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1. Introduction 
1.1 α2m 
Alpha 2 macroglobulins (α2m) are a family of abundant plasma proteins best known for 
their ability to inhibit broad spectrum of proteases. α2m is the major representative of 
the alpha macroglobulin family that also comprises pregnancy zone protein (PZP) and 
complement components C2 and C3 (Jensen 1989, Borth 1992). Its structural and 
functional properties make it a very unique protein because of its protease trapping 
mechanism. Besides proteinase inhibition it also functions as a carrier of cytokines and 
growth factors by covalently binding to them thereby linking its role in growth promoting 
activities by targeting the α2m-cytokine/growth factor complex to α2m receptor 
expressing cells (Birkenmeier et al., 2003, Esadega et al., 2003). α2m is known to bind 
to two distinct receptors namely LRP1 and GRP78 which are expressed on several 
tissues.  
α2m is a typical acute phase protein in many mammalian species such as rabbit, rat, 
mouse and humans with its concentration increasing several-fold upon diseased states 
like pancreatitis, multiple sclerosis, sepsis etc. Several groups have described the anti-
inflammatory effects of α2m, for example in induced hepatitis, in burn trauma, 
anaphylactic shock and in inflammation caused by histamine, bradykinin or 
prostaglandins (Hochepied et al., 2000). Oxidation of α2m increases its binding affinity 
to inflammatory mediators like TNFα thereby inhibiting progression of the inflammatory 
cascade (Wu et al., 1998). α2m was also reported to play a role in immunity where α2m 
isolated from blood of tumor bearing mice was bound with tumor antigens that were 
immunogenic (Pawaria et al., 2012). α2m also inhibits coagulation and fibrinolysis by 
binding to thrombin and plasmin respectively (Schaller et al., 2011). α2m was reported 
to possess chaperone activity by binding to unfolded proteins resulting from heat or 
oxidative stress and their subsequent disposal (Wyatt et al., 2013). α2m facilitates 
removal of various disease associated proteins like β2-microglobulin in amyloidosis, 
prion protein in Creutzfeldt-Jakob disease and Amyloid β in Alzheimer’s disease (Wyatt 
et al., 2013). 
α2m is predominantly synthesized by the liver and is mainly present in plasma, 
cerebrospinal fluid and other extravascular fluids. α2m is also locally produced by 
fibroblasts, monocytes, macrophages, hepatocytes and astrocytes (Jensen 1989).  
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1.1.1 Structure 
The primary structure of α2m was elucidated by Sottrup-Jensen et al. in 1983. It has a 
molecular weight of 720 KDa and is the largest protease inhibitor known. It is a homo-
tetramer consisting of four identical subunits each of 180 KDa where two subunits are 
joined by a disulphide bond and these two pairs are covalently linked to each other 
forming a cylindrical structure with an enclosed central cavity. Each α2m subunit 
contains four distinct regions; the bait region, growth factor binding domain, the β-
cysteinyl-γ-glutanyl thiol ester containing domain and a receptor recognition site. The 
bait region contains a specific set of amino acids where serine, cysteine, aspartic and 
metallo-proteinases gets bound. The thiol ester rupturing imparts α2m its 
conformational structural change with α2m receptor exposure. Growth factors and 
cytokines are known to bind to growth factor binding site covalently and non-covalently 
to other sites (Wyatt et al., 2013). 
 
Figure 1.1.1: α2m structure and domains within α2m subunit. A: representation of a single 
180 KDa α2m subunit, B: α2m homo-tetramer joined by disulphide bonds (Courtesy: Feldman et 
al., 1985) C: Representation of domains present in each α2m subunit. The numbers denote the 
amino acid sequence in which each domain is present. (Modified from Mettenburg et al., 2002) 
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1.1.2 Protease binding and clearance by α2m 
Native α2m found in the plasma is not recognized by its receptors. The inhibition of 
proteinases by α2m is a unique mechanism. As illustrated in Figure 1.2 upon a 
protease binding to a native α2m, the bait region gets cleaved trapping the protease in 
its cage like structure. This protease then forms a covalent linkage with the thiol ester 
bond which subsequently ruptures and induces a conformational change. This 
structural change in the α2m molecule results in the exposure of a cryptic recognition 
site at the carboxyl terminus of each α2m subunit and results in the activated form of 
α2m (Misra et al., 2006). Other than proteinases small nucleophiles like methylamine or 
ammonia can also rupture the thiol esters resulting in the activated form. Proteinase 
binding to α2m is irreversible but the active site of proteinase remains 80 – 100% active 
against low molecular substrates (French et al., 2008). Once in active form, this 
protease-α2m complex gets recognized by α2m receptors LRP1 and GRP78. Upon 
binding to LRP1, the complex gets rapidly cleared via receptor mediated endocytosis. 
On the other hand when bound to GRP78 it can mediate several cellular signaling 
pathways. The active form of α2m migrates faster on gel electrophoresis under non 
denaturing conditions compared to the native form because of its compact structure 
(Bhattacharjee et al., 2000). 
 
 
Figure 1.1.2: α2m activation and receptor recognition. Native α2m is having an open 
structure. Upon activation by a nucleophile or protease structural change is induced which is 
recognized by its receptors LRP1 and GRP78 
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1.1.3 Growth factor binding to α2m 
Numerous cytokines and growth factors are known to bind to α2m to regulate their 
physiological activity. Among them are transforming growth factor β (TGF-β), platelet-
derived growth factor (PDGF), nerve growth factor (NGF), β-nerve growth factor (β-
NGF), tumor necrosis factor a (TNFα), basic fibroblast growth factor (bFGF), interleukin 
(IL-6), interleukin 2 (IL-2) and vascular endothelial growth factor (VEGF). The cytokine 
and growth factor can bind to both native and activated forms of α2m.  α2m acts both 
as a carrier protein in case of growth regulated processes and in clearance of cytokines 
in case of inflammatory conditions. VEGF has been shown to bind to α2m to a site 
other than the growth factor binding domain and that it binds to methylamine activated 
α2m to the interior and to the exterior of native and proteinase activated α2m 
(Bhattacharjee et al., 2000). Other studies have also demonstrated that inflammatory 
cytokines like TNFα, IL-2 and IL-6 exhibited increased affinity to bind to oxidized forms 
of native and activated α2m while growth factors like β-NGF, PDGF-BB, TGF-β1 and 
TGF-β2 showed decreased binding suggesting oxidation of α2m to be involved in down 
regulating progression of inflammation and up regulating tissue repair processes by 
releasing growth factors (Wu et al., 1998).  
1.1.4 Implications of α2m 
In rats, α2m is an acute phase protein with its concentration increasing 50 fold within 24 
h under inflammatory conditions (Sultan et al., 2012). Treatment of rats with α2m 
enriched autologous plasma has been reported to diminish the progression of 
pancreatic damage in experimental pancreatitis (Di Loreto et al., 2012). α2m was 
reported to play a central role in survival upon irradiation with x-rays by activation of the 
IL6/JAK/STAT3 hepatoprotective signaling pathway (Mirjana et al., 2010). α2m 
treatment in rat ventricular cardiomyocytes was reported to induce hypertrophy by 
activating ERK and PI3K/AKT pathways (Padmasekar et al., 2007). 
α2m like protein in zebra fish was shown to be essential for liver organogenesis, where 
its knock down resulted in disruption of growth and development of the liver with 
reduced cell proliferation without observable defects in pancreas and intestine (Hong et 
al., 2008). 
α2m double knockout mice were viable and fertile, proving that α2m is not essential 
during embryonic development or adult life, but necessary during implantation and 
trophoblast invasion exerting its role in tissue remodeling both as a proteinase inhibitor 
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and TGFβ binding molecule (Esadeg et al., 2003). Upon induction of acute pancreatitis 
in double knockout mice mortality was 70% suggesting α2m to play an important role 
both as a protease inhibitor and as a carrier protein since mRNA levels of Lt-β, TNFα, 
IFN-Ɣ, and TGF-β1 were increased (Umans et al., 1999). Mouse α2m was also 
reported to be a functional homologue of human α2m (Hudson et al., 1987). 
Human α2m is the most widely studied one. In humans, α2m is a single-copy gene 
located on chromosome 12p12-13 also comprising the PZP gene. It is found in the 
plasma at a concentration of 4-5mg/ml and declines to 2-4mg/ml by adulthood (Tayade 
et al., 2007). Removal of α2m from blood significantly increases plasma protein. A 
cardiac isoform of α2m has been reported as an early marker for cardiac hypertrophy 
and its elevated upon myocardial infarction in diabetic patients (Annapoorani et al., 
2006). The endothelial cells lining the endometrial blood vessels were reported to 
produce α2m with its concentration increasing 2-3 folds during the proliferative phase of 
menstrual cycle. This suggests a role in endometrial physiology and in the physiology 
of embryo development and implantation (Sayegh et al., 1997).  
1.2 LRP1 
Low density lipoprotein receptor related protein 1 (LRP1) is a member of the LDL 
receptor family mainly implicated in endocytosis of various ligands and in mediation of 
various cell signaling pathways. It was identified to be the receptor responsible for 
clearing α2m-proteinase complexes found in plasma. Other than α2m-proteinase 
complexes, LRP1 recognizes and binds to 40 other various ligands known till date 
ranging from lipoproteins, ECM proteins, protease-inhibitory complexes, viruses, 
cytokines and growth factors. LRP1 is expressed in  liver, lung, brain and in multiple 
cell types like fibroblasts, VSMCs, neurons, astrocytes, macrophages and cultured 
brain capillary endothelial cells. The expression of LRP1 in human endothelial cells is 
somewhat controversial as bovine aortic endothelial cells in culture were found to 
express LRP1 but not human aortic endothelial cells, human coronary artery 
endothelial cells and human neonatal dermal micro vascular endothelial cells (Lillis et 
al., 2008). LRP1 is known to shuttle continuously between the cell surface and 
cytoplasmic vesicles. LRP1 is essential for normal development in the mouse, as 
homozygous knockout animals die at day 9 of gestation (Herz et al., 1992). 
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1.2.1 LRP1 Structure 
LRP1 is a 600 KDa protein composed of a 515 KDa α-subunit and an 85 KDa β-
subunit. Like all other members of the LDL receptor family, LRP1 structure contains an 
extracellular transmembrane domain and a cytoplasmic domain which are non-
covalently linked. The extracellular domain is mainly composed of clusters of cysteine 
rich complement type repeats (CR), EGF repeats and β propeller domains. CRs are the 
ligand binding sites and are present as clusters, termed clusters I - IV. Most ligands 
including α2m are known to bind to clusters II and IV (Lillis et al., 2008). EGF repeats 
and β propeller domains are known to function in uncoupling of ligands in endosomal 
compartments. The cytoplasmic domain encompasses 100 amino acids with two di-
leucine motifs and two NPxY motifs, which bind to various adaptor molecules and are 
known to be involved in cellular traffic and cell signaling. Cell signaling by LRP1 is 
triggered upon phosphorylation of tyrosine and serine residues present in the 
cytoplasmic domain (van der Geer P 2002). 
 
Figure 1.2.1: Representation of LRP1protein structure. CI-CIV are the cluster binding 
domains within the α-subunit. The β-subunit comprises part of cytoplasmic domain, 
transmembrane domain and the intracellular domain. (Modified from Lillis et al., 2008) 
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1.2.2 LRP1 functions 
LRP1 upon ligand binding principally has three major functions which are endocytosis, 
cell signaling and co-receptor activity. Depending on its presence in various tissues and 
cells, these few actions subsequently get it involved in many physiological activities like 
inflammation, proliferation, migration, permeability, phagocytosis, immunity, 
angiogenesis etc. Few of which are described below:  
Hepatic LRP1 besides clearing α2m protease complexes from blood plasma also 
facilitates catabolism of serpin-enzyme complexes like tissue plasminogen activator 
(tPA) and Urokinase-type plasminogen activator (uPA), the blood coagulation factor VIII 
and certain Apolipoprotein E rich lipoproteins maintaining normal homeostasis of liver 
and protection against atherosclerosis as hepatic LRP1 KO mice showed two fold 
increase in atherosclerotic lesion compared to normal mice (Lillis et al., 2008). LRP1 in 
the brain is known to regulate the progression of AD by apolipoprotein E mediated 
amyloid Aβ clearance in the brain (Holtzman et al., 2012). 
LRP1 in inflammation: LRP1 modulates lipopolysaccharide signaling in murine 
macrophages reducing inflammatory responses by proteolytically releasing its 
intracellular domain to the nucleus where it interacts with IRF3 (Lillis et al., 2008). Also 
Lactoferrin binding to LRP1 inhibits NFκB activation and production of pro-inflammatory 
cytokines (Beisiegel et al., 1998). Macrophage uptake of apoptotic cells is mediated by 
LRP1 by recognizing calreticulin on the target cells with its eventual phagocytosis and 
degradation thereby resolving inflammation (Nilsson et al., 2012). 
LRP1 in growth factor mediated cell signaling: LRP1 is reported to regulate BMP4-
mediated endothelial function and vascular development, since LRP1 mouse 
endothelial knock down cell lines failed to migrate and induce angiogenesis in presence 
of BMP4 (Pi et al., 2012). LRP1 is involved in signaling processes that involve TGFβ, 
PDGF, and their receptors in mediating atherosclerosis in VSMC. Deficiency in LRP1 
activates PDGF-BB and PDGRβ, phosphorylating SMAD2, a downstream component 
of the TGFβ pathway promoting atherosclerotic lesion formation (Boucher et al., 2011). 
Moreover TGFβ receptor TGFR-V was identified to be LRP1 in mediating growth 
inhibitory response of TGFβ in conjunction with SMAD2/3 signaling. LRP1 was also 
shown to be associated with PDGF receptor in the endosomal compartment where they 
form a signaling complex modulating PDGF signaling cascades that involve MAPK and 
Akt/PI3K pathways. PDGF, a key regulator for cellular proliferation and migration, also 
mediates the tyrosine phosphorylation of LRP1 at its cytoplasmic domain (Muratoglu et 
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al., 2010). In VSMC, LRP1 complexes with PDGFR-β to modulate actin organization 
and migration by activating PDGFR-β-dependent activation of PI3K-PDGF-mediated 
signaling (Boucher et al., 2002). 
1.2.3 LRP1 antagonist, RAP 
Receptor associated protein (RAP) a 39 KDa protein was discovered by ligand-affinity 
chromatography where it was co-purified with LRP1 (Ashcom et al., 1990). It is an 
LRP1 antagonist which can inhibit binding of all known ligands to LRP1. RAP is an ER-
resident protein that binds to multiple sites on LRP1 and also acts as an LRP1 
chaperone. Premature association with ligands of newly translated LRP1 is prevented 
by RAP being transiently bound to LRP1 in the ER until it is successfully delivered to 
the cytoplasmic membrane. In RAP deficient mice processed LRP1 was found to be 
less expressed in brain and liver (Lillis et al., 2008). 
 
1.3 GRP78 
In addition to the well characterized LRP1 receptor, a second receptor for α2m was 
reported by Misra et al., in 1994. Binding of activated α2m to GRP78 activates pro-
proliferative, anti-apoptotic, and pro-migratory signaling cascades in tumor cells (Misra 
et al., 2013). GRP78 is a 78 KDa glucose-regulated protein also referred to as the 
immunoglobulin binding protein, BiP are members of the ER chaperone family 
discovered in the 1980’s as proteins inducible by glucose starvation (Langer et al., 
2008). It is widely used as a marker for ER stress as its expression gets highly induced 
in the ER under stress conditions (Ni et al., 2011). This ER chaperone belongs to the 
HSP70 family playing a central role in regulating the unfolded protein response (UPR) 
(Buchkovich et al., 2009). GRP78 function is thought to be critical for eukaryotic cell 
function as its amino acid sequence is highly evolutionarily conserved from yeast to 
human (Ting et al., 1988). 
GRP78 double knock out mouse embryos exhibited lethality beyond the peri-
implantation stage and failed to grow in culture and to exhibit proliferation. Hence 
GRP78 is essential for embryonic cell growth and pluripotent cell survival (Luo et al., 
2006) 
GRP78 is expressed on the cell surface of proliferating endothelial cells and prostate 
cancer cells (Ni et al., 2011). It is primarily located in the ER lumen of non-stressed 
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cells with a sub fraction detected as transmembrane protein. Beyond the ER 
mitochondrial, nuclear and secreted forms of GRP78 have been identified and linked to 
cellular homeostasis. It is also highly expressed in the developing embryo and in the 
embryonic brain linking its role in neurological disorders (Weng et al., 2011) 
1.3.1 GRP78 structure  
GRP78 is composed of three domains: the N-terminal ATPase domain, the peptide-
binding domain, and a C-terminal domain. The unfolded peptides are bound to the 
peptide-binding domain and use energy by hydrolyzing ATP to promote proper folding 
and aggregation of the peptide (Luo et al., 2006). The function of the C-terminal domain 
is unknown but upon cell surface translocation all three domains are exposed to the cell 
surface speculating its role in ligand recognition (Ni et al., 2011). Upon α2m binding to 
GRP78, the N-terminal undergoes auto-phosphorylation triggering pro-proliferative, 
anti-apoptotic, and pro-migratory signaling cascades in tumor cells (Misra et al., 2013). 
1.3.2 GRP78 functions 
ER stress signaling: GRP78 regulates UPR signaling by a bind-and-release 
mechanism with the ER stress sensors and transducers: PERK, ATF6 and IRE1 (Weng 
et al., 2011). UPR is normally controlled by trans-membrane sensors which initiate the 
complex UPR signaling where under unstressed conditions GRP78 is believed to bind 
to these sensors and keep them inactive. However under ER stress, when unfolded 
proteins accumulate in the ER, GRP78 leaves these sensors to perform its chaperone 
function, thus allowing the sensors to activate UPR signaling (Buchkovich et al., 2009). 
ER stress also induces GRP78 transcription resulting in its upregulation along with a 
cytosolic form of GRP78, called GRP78va. Cell surface GRP78 emerges as an 
important receptor in cell signaling, viability and anti-apoptotic signaling pathways (Ni et 
al., 2011). In the ER lumen GRP78 associates with co-chaperones enhances protein 
folding and degradation of misfolded proteins whereas GRP78va activates PERK 
signaling increasing cell survival under ER stress. GRP78 also regulates mitochondrial 
function especially under ER stress by balancing energy expenditure and maintaining 
mitochondrial calcium homoeostasis (Ouyang et al., 2011). 
Cell proliferation: In cancer cells cell-surface GRP78 interaction with α2m was 
reported to regulate cell proliferation pathways by activating ERK1/2, MAPK and PI3K 
and cell survival pathways by activating the Akt and NFκB (Buchkovich et al., 2009). 
Cell surface GRP78 was also reported to play an important role in endothelial cell 
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proliferation and in anti-apoptosis signaling. One study reported this receptor to be 
associated with Glycosyl Phosphatidylinositol (GPI) anchoring T-Cadherin, thereby 
influencing cell survival in vascular endothelial cells. Another study revealed blocking of 
GRP78 receptor with recombinant Kringle 5, an angiogenesis inhibitor induced 
apoptosis of proliferating endothelial cells and tumour cells enhancing Caspase7 
activity. Cell surface GRP78 was reported to be elevated in VEGF treated HUVEC cells 
revealing its active role in endothelial cell proliferation (Ni et al., 2011). 
Virus internalization: GRP78 is known to act as a co-receptor with MHC class I 
molecules on the cell surface of host cells in mediating virus internalization. Viruses like 
Coxsackie virus A9, dengue virus serotype 2, human cytomegalovirus and Borna 
disease virus were reported to be bound to GRP78. Antibody blocking against cells 
expressing GRP78 resulted in reduction of virus infection (Ni et al., 2011).  
 
1.4 Stem cells  
Stem cells are undifferentiated or unspecialized cells found in multicellular organisms 
which have remarkable potential to form any kind of cell in the adult organism (Figure 
1.4). Stem cells have two very important characteristics that make them different from 
other kind of cells; these are its ability of self-renewal and its differentiation capacity 
(Takahashi et al., 2007). Self-renewal is characterized by its potential to divide 
mitotically yet remaining in the undifferentiated state. The differentiation capacity is 
characterized by the ability of stem cells to differentiate into any kind of specialized cell 
under appropriate stimulation, i.e. types like nerve cell, blood cell, skin cells etc. Other 
than stem cells, no other cell in the multicellular organism has the ability to generate 
terminally differentiated cells with specialized functions. The pluripotency of ESCs is 
governed by expression of the core transcription factors Nanog, Oct4, and Sox2 which 
are known to down-regulate the expression of developmental genes while regulating 
transcriptionally active genes involved in pluripotency maintenance (Chen et al., 2008, 
Saunders et al., 2011). 
The potency of stem cells is further classified into totipotent, pluripotent, multipotent, 
oligopotent and unipotent depending on its differentiation capacity into a whole 
organism or a specific set of specialized cells. The main sources of stem cells are 
described below: 
  
11 
 
 
Figure 1.4: Differentiation capacity of pluripotent stem cells. Upon fertilization of an egg, 
the cells divide to give to totipotent stem cells that form a blastocyst. The differentiation capacity 
of pluripotent stem cells derived from the inner cell mass of blastocyst to form specialized cells 
of all three germ layers is illustrated. (Modified from www.sigmaaldrich.com) 
 
Embryonic stem cells: As the name suggests these cells are derived from 3-5 day old 
embryo from its inner cell mass at the blastocyst phase. These ESCs are totipotent and 
can differentiate into all three germ layers: ectoderm, endoderm and mesoderm. The 
isolated ESCs can be cultured in vitro and maintained in undifferentiated state. These 
cells are a very valuable source for studying early stages of embryonic development.  
Adult stem cells: Adult stem cells are multipotent cells found in organisms at the adult 
stage in various tissues. They have been identified in many organs and tissues 
throughout the adult body like bone marrow, umbilical cord blood, skin, blood, hair 
follicle, liver etc. They are thought to reside in specific areas of the tissues in a 
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quiescent state until they are activated. They are lineage restricted and primarily 
function to repair, replenish or regenerate the tissue in which they are present. Adult 
stem cells have already entered into therapeutics with bone marrow transplants 
performed to treat leukemia. 
Induced pluripotent stem cells: These cells also called iPSCs are created by 
scientists in the laboratory where terminally differentiated cells from the adult organism 
are engineered or reprogrammed to behave and function like pluripotent stem cells. 
Mouse iPSCs were first generated by Shinya Yamanaka’s team in Japan in 2006 by 
retroviral transduction of four factors: Oct4, Sox2, c-Myc, and Klf4 into mouse 
fibroblasts (Takahashi 2006). The iPSC generation led to an important breakthrough in 
stem cell research as they hold great promise in creating disease specific or patient 
specific cell lines for therapeutic research purposes (Ma et al., 2013). 
1.4.1 Embryonic stem cell lines 
Various mouse and human ESC lines were established for research purposes that can 
be grown and expanded in culture indefinitely in the undifferentiated state. Mouse 
ESCs were first isolated and cultivated by Evans and Kaufmann in 1981 along with 
Martin in 1981. Human ESCs were first isolated by Thomson et al., in 1998 (Evans et 
al., 1981, Martin 1981). 
These cells are cultured on cell culture dishes coated with feeder layers of MEFs which 
provide them a sticky surface for attachment and growth. They proliferate by forming 
colonies. Mouse ESC lines can be maintained in undifferentiated conditions by 
culturing them with medium containing LIF which promotes self-renewal by activating 
PI3K/AKT and JAK/STAT3 signaling pathways. However human ESC lines in culture 
do not require LIF but the growth factor FGF2 for self-renewal, FGF2 acts by activating 
MAPK and Activin/Nodal signaling pathways. The ESC lines are characterized routinely 
by their expression profiles of transcription factors and cell surface markers. They can 
also be injected into immune suppressed mouse for teratoma formation which is an 
indication of their differentiation capacity. 
Upon withdrawal of self-renewal cytokines from cell culture, the ESCs start to 
spontaneously differentiate into various kinds of cells. This spontaneous differentiation 
can be directed towards a specific cell type by altering the composition of the medium 
by adding various stimulants or inhibitors. EBs are three dimensional aggregates of 
ESCs which mimic the early development processes of a normal embryo by undergoing 
differentiation into all three germ layers.  
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1.4.2 ESC implications 
Study developmental processes: ESCs are a remarkable cell source for researchers 
and scientists for understanding early developmental processes that occur beginning 
from the fertilization of the egg. The regulation of various genes involved and their 
molecular cues give insight into the fundamental processes of how organisms grow and 
develop.  
Study diseases and drug screening: The differentiated stem cell lines offer a 
remarkable source for drug screening and research compared to in-vivo studies 
performed in humans and animals. A more advanced approach is the development of 
patient-specific or disease-specific stem lines to study human diseases at a much 
closer level which could replace the use of experimental animal models (Mori et al., 
2013). 
Regenerative medicine: The most potential application of stem cells is for replacing 
diseased, aged or damaged tissues, an approach called regenerative medicine. Stem 
cells which can be directed to differentiate into a particular type of tissue offer the 
possibility to replace the damaged cells and tissues. Currently stem cells are being 
used to treat various blood disorders and are proposed to be utilized to treat various 
diseases like spinal cord injury, burns, heart disease, diabetes, arthritis etc. (Chopra et 
al., 2013) 
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1.5 Vasculogenesis 
During embryo development, the vascular system is the primary structure that forms 
within the developing organism for oxygen, nutrient supply and waste removal. The 
vascular system arises from haemangioblasts which give rise to angioblasts from which 
blood vessel develops and hematopoietic stem cells that form the blood cells. 
Formation of blood vessels and blood cells is crucial for the developments of all other 
organs and any disruption in their formation leads to mortality (Carmeliet 2005). 
Vasculature which is the formation of blood vessels occurs by two distinct mechanisms: 
vasculogenesis which is the de-novo formation of blood vessels from endothelial 
precursor cells (EPCs) and subsequently by angiogenesis which is the expansion of 
the vascular network from the primitive vascular structures by formation of mature 
blood vessels (Kässmeyer et al., 2009, Velazquez 2007). Blood vessel development 
plays a key role in human physiology ranging from fetal growth, reproduction, wound 
healing and tissue repair and also in pathologies like tumor growth. 
 
 
 
Figure 1.5: Vasculogenesis and angiogenesis of the vascular system. (Coutesy: Carmeliet 
2005) 
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Vasculogenesis is largely restricted to early embryonic development and angiogenesis 
to late embryogenesis until adult hood. Vasculogenesis is driven by the recruitment of 
EPCs of angioblasts which are of mesodermal origin and their differentiation into the 
endothelial cell lineage with de novo assembly of these cells into a primitive vascular 
network. Subsequently angiogenesis is triggered upon angiogenic stimuli; EC 
permeability of the blood vessel increases with EC cell proliferation and migration, 
thereby forming a new capillary along with its maturation.  
Angiogenesis is a highly regulated process that involves many growth factors and their 
signal transduction. Angiogenic growth factors, e.g. VEGFs and FGFs stimulate 
endothelial cells to secrete proteases and plasminogen activators, which result in 
protein degradation and migration of ECs. These ECs cells migrate, proliferate and 
eventually differentiate to form a new lumen containing vessel and further secrete the 
growth factor PDGF that attracts pericytes and SMCs forming a multicellular blood 
vessel structure and their stabilization (Drake 2003, Tang et al., 2004). 
1.5.1 Growth factors and cell signaling pathways involved in 
vasculogenesis 
 
VEGF: (VEGFs) are secreted proteins which are key promoters of angiogenesis and 
vascular development. VEGFs are comprised of five members in mammals: VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF) (Stacker SA et al., 
2013). The most widely studied is the VEGF-A with different isoforms of VEGF121, 
VEGF165, VEGF189, and VEGF206. VEGF binds to receptor tyrosine kinases VEGFR 
1-3 and co-receptors neuropilins (NRPs) and heparan sulphate proteoglycans (HSPGs) 
(Robinson et al., 2001). VEGFs are primarily secreted by endothelial, hematopoietic, 
and stromal cells upon hypoxia and upon stimulation by growth factors such as TGFβ, 
interleukins and PDGFs (Stuttfeld et al., 2009). The VEGFRs mainly function in 
cardiovascular, haematopoietic and lymphatic development (Olsson et al., 2006). A 
single allele VEGF-A knockout results in lethality at embryonic day 11 due to deficient 
EC development (Carmeliet et al., 1996). Activation of VEGFR2 regulates the most 
angiogenic signaling pathways. VEFGR2 gets phosphorylated at Tyr1054 and Tyr1059 
thereby activating PLCγ and PI3K. PLCγ activates intracellular calcium and ERK1/2, 
resulting in the proliferation of ECs. PI3K activation leads to the downstream activation 
of AKT in survival of ECs and regulates NO production (Olsson et al., 2006). 
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Figure 1.5.1: Angiogenesis signaling pathways (Courtesy: www.cellsignal.com) 
 
FGF2: Fibroblast growth factor 2 is a potent angiogenic growth factor that induces 
endothelial migration and proliferation (Kottakis et al., 2011). It is one of the 23 
members of FGF family which are involved in angiogenesis, wound healing, embryonic 
development and tumor growth. FGFs bind to receptor tyrosine kinases FGFR 1-5. The 
FGFs are heparin binding proteins and heparan sulfate proteoglycans (HSPGs) 
regulate FGF activity by acting as a co-receptor. FGFR gets activated upon auto-
phosphorylation of the tyrosine residues present in the intracellular region of the FGF 
receptor. The binding of FGF2 to its receptors leads to the activation of downstream 
signaling pathways such as JAK/STAT, PLCγ, PI3K/Akt and MAPK/ERK, thus 
stimulating cell proliferation and differentiation (Lau et al., 2013, Lanner et al., 2010).  
PDGF-B: Platelet-derived growth factor (PDGFs) comprises of four ligands PDGF A 
until D and two tyrosine kinase receptors PDGFRα and PDGFRβ which are involved in 
cell growth and proliferation. They also play a significant role in angiogenesis. PDGF-B 
and PDGFR-β double KO mouse are lethal leading to mortality due to hemorrhaging 
and edema formation (Stratman et al., 2010 and Meinecke et al., 2012). PDGF-B exists 
as the dimer PDGF-BB, which is produced by ECs and functions in recruitment of mural 
cells to stabilize the newly formed vessels (Wijk et al., 2013). PDGFRβ gets 
phosphorylated at Tyr-857 and activates MAPK, PLCγ and PI3K pathways. ROS-
dependent STAT3 activation has been reported to be a downstream mediator of 
PDGFR signaling in VSMCs (Blazevic et al., 2013). 
Besides above mentioned growth factors various other factors are also involved in the 
process of angiogenesis. Growth factors like TGFβ1 function in embryonic vascular 
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assembly by promoting cellular differentiation into pericytes and VSMCs and in the 
establishment and maintenance of vessel wall integrity. Hepatocyte growth factors 
(HGF) are involved in regulating expression of VEGF, VEGFR2 and thrombospondin-1 
(TSP1). Regulation of angiogenesis also depends on the balance between pro-
angiogenic factors and anti-angiogenic factors like TSP1, platelet factor 4 (PF4) and 
endostatin. TSP1 and PF4 modulates angiogenesis by binding to VEGF165 and FGF2 
respectively preventing their binding to their receptors. SHH plays role by up regulating 
angiogenic growth factors. Notch family of proteins and their activation regulates EC 
sprouting with formation of tip cells and stalk cells (Wijk et al., 2013). The Slit proteins 
and their Robo receptors function in axon guidance and are implicated in permeability 
and migration (Yuen et al., 2013).  
Clinical applications of angiogenesis: 
Abnormal angiogenesis causes numerous diseases. Ischemic diseases are caused 
due to decrease in angiogenesis; in diseases like cancer there is excessive 
angiogenesis. Angiogenesis can be manipulated and utilized for clinical application 
where angiogenesis stimulator can be used to induce therapeutic angiogenesis. 
Regranex, a recombinant human PDGF-BB is used for diabetic foot ulcer disease. Anti 
angiogenic factors like Avastin, an anti-VEGF monoclonal antibody, are attenuating 
excessive angiogenesis and are used for treatment of cancers (Carmeliet et al 2011).  
Besides acceleration and inhibition of angiogenesis, the quantification of angiogenesis 
in a biopsy specimen can be utilized for diagnostic and prognostic applications to 
assess the risk of metastasis or recurrence.  
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1.6 Aim of the study 
 
The acute phase protein α2m which is a protease inhibitor and a growth factor carrier 
protein is speculated to be involved in tissue remodeling processes under normal and 
inflammatory conditions. In a developing embryo, various signaling pathways are 
activated in a highly coordinated manner to ensure proper development and 
morphogenesis. A differentiating mouse EB is a replica of a developing embryo and 
administration of α2m during its development is hypothesized to activate various 
signaling pathways pertaining to differentiation. α2m exerts its effects through its 
receptors LRP1 and GRP78 which are known to activate various growth factor cell 
signaling pathways. The aim of this research project was to investigate the effects of 
α2m on vasculogenesis in the differentiating mouse EB.  
The specific aims of this study were as follows:  
1. Study endogenous expression of α2m and its receptors in differentiating mEBs 
2. Investigate the effects of exogenous application of α2m on differentiating mEBs 
and examine its impact on vasculogenesis 
3. Determine the activity of the α2m receptors by blocking them with specific 
antibodies or known inhibitors 
4. Investigate the regulation of growth factors in differentiating mEBs upon α2m 
treatment 
5. Elucidate the signaling pathways activated upon α2m treatment in mEBs 
6. Access the functional activity of α2m on sprouting assay of mESC spheroids 
7. Analyze the anti-inflammatory role of α2m and expression of α2m and its 
receptors  upon induction of inflammation in mEBs with TNFα 
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2. Materials 
2.1 General laboratory materials  
 
4 well cell culture plate  Nunc, Thermo Scientific, USA 
6 well cell culture plate  BD falcon, USA 
Bacterial culture dish   Greiner bio-one, Germany  
Blotting chamber    Xcell II Blot module, Life Technologies, Germany 
Cell scrapper     Corning, USA 
Conical flasks    Fischerbrand, Fischer Scientific, Germany 
Conical tubes 15ml, 50ml   Greiner bio-one, Germany 
Cover slips    Deckgläser, Menzel-Gläser, Germany 
Cryovial    Sarstedt, Germany 
Electrophoresis chamber Xcell SureLock Mini-Cell, Life Technologies, 
Germany  
Filter paper for blotting  Universal, Biotech Fischer, Germany 
Filter     Stericup & Steritop, Millipore, Germany 
Glass slides    R.Langenbrinck, Germany 
Microcentrifuge tubes   Sarstedt, Germany 
Multichannel pipette   Transferpette S8/12, Brandtech Scientific, USA 
Nalgene Mr.Frosty   Thermo Scientific, USA 
Nitrile gloves    Ansell Healthcare Europe, Belgium 
Nitrocellulose membrane   Whatman™ GE Healthcare, Germany  
NUPAGE® 4-12% Bis-Tris Gel Life Technologies, Germany 
Parafilm    Bemis Flexible Packaging, USA 
Pipette filter tips   Biozym Scientific, Germany 
Pipette tips    Sarstedt, Germany 
Serological glass pipettes  ISO Lab, Germany 
Serological plastic pipettes  BD falcon, USA 
Spinner flask     Cellspin 250, Integra biosciences, Germany 
Sponge Pad for blotting  Life Technologies, Germany 
Storage bottles   Schott Duran, UK 
Tissue culture treated dish  BD falcon, USA 
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2.2 Instruments 
 
-80ºC Freezer     HERAFreeze, Heraeus, Germany 
Aspirator     HLC, Kobe, Germany 
Autoclave     Holzner GmbH, Germany  
Cell culture bench    HERAsafe, Heraeus, Germany 
Cell culture incubators   HERAcell 240, Heraeus, Germany 
      HERAcell 150, Heraeus, Germany 
Centrifuges     Eppendorf 5417C, Germany   
Multifuge 1S-R centrifuge, Heraeus, 
Germany   
Labofuge 300 centrifuge, Heraeus, 
Germany   
Chemiluminescence imaging system  Peqlab Biotechnologie, Germany  
Confocal microscope Leica SP2 AOBS, Leica Microsystems, 
Germany  
ELISA reader Magellan Infinite M200, Tecan, 
Switzerland 
Gel electrophoresis power station PowerEase®500, Life Technologies, 
Germany  
Heating block     TB2 Thermoblock, Biometra, Germany 
Homogenisor      Pellet Pestle Motor, Sigma, Germany 
Ice machine     Icematic F200, Castel MAC, Italy 
Light microscope    Axiovert 40C, Zeiss, Germany 
Liquid nitrogen tank    Air Liquide, France 
Magnetic stirrer for spinner flask  Integra biosciences, Germany 
Magnetic stirrer    RH-KT/C, IKA, Germany 
pH meter     pH 211, HANNA Instruments, Germany 
Pipettes     Gilson, USA  
Pipette filler Pipetus, Hirschmann Laborgerate, 
Germany 
Power station for WB PowerEase 500, Life Technologies, 
Germany 
Safety Bunsen burner    Fireboy, Integra biosciences, Germany 
Shakers/Rockers  Mini see-saw-rocker SSM4, Stuart, UK 
Vortexer      Vortex genie 2, VWR, Germany 
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Waterbath     Hirschmann, Germany  
Weighing machines     TE153S Sartorius, Germany  
AB265S Mettler Toledo, USA   
 
2.3 Proteins and Enzymes 
 
α2-macroglobulin, human plasma  Calbiochem, USA (Cat no. 441251) 
Aprotinin, bovine lung    Calbiochem, USA (Cat no. 616370)  
Bovine serum albumin    Gentaur, Germany (Cat no.BAH65) 
Collagenase B    Roche, Germany (Cat no. 11088815001) 
ESGRO Leukemia Inhibitory Factor  Millipore, Germany (Cat no.ESG1107) 
FGF2, recombinant human   Sigma-Aldrich, Germany (Cat no. F0291)  
Fibrinogen, bovine plasma    Calbiochem, USA (Cat no. 341573) 
Nonfat dried milk powder    AppliChem, Germany (Cat no. A0830) 
PDGF-BB, recombinant human  R&D Systems, UK (Cat no. 220-BB) 
Phosphatase inhibitor cocktail 3   Sigma-Aldrich, Germany (Cat no. P0044) 
Protease inhibitor cocktail    BioVision, USA (Cat no. K271-500) 
RAP, recombinant    R&D Systems, UK (Cat no. 4480-LR) 
Thrombin, bovine plasma    Sigma-Aldrich, Germany (Cat no. T7513) 
TNF-α, recombinant mouse   Millipore, Germany (Cat no.GF023) 
Trypsin EDTA 1X Life Technologies, Germany (Cat no.  
25300-062) 
VEGF 165, recombinant human  R&D Systems, UK (Cat no. 293-VE) 
  
2.4 Inhibitors 
 
AG1296 (PDGFR inhibitor)   Calbiochem, USA (Cat no. 658551) 
AG490 (JAK2 inhibitor)   Calbiochem, USA (Cat no. 658401) 
Compound C (AMPK inhibitor)  Calbiochem, USA (Cat no. 171260) 
LY294002 (PI3K inhibitor)   Calbiochem, USA (Cat no. 440202) 
PD98059 (ERK1/2 inhibitor)   Calbiochem, USA (Cat no. 513000) 
SU5402 (FGFR2 inhibitor)   Calbiochem, USA (Cat no. 572630)  
SU5614 (FLK1 inhibitor)   Calbiochem, USA (Cat no. 572632) 
Wortmannin (PI3K inhibitor)   Calbiochem, USA (Cat no. 681675) 
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2.5 Cell lines 
 
MEF: Derived from C57BL/6 mouse embryos at 12.5 day gestation 
MES: CCE S103, 129/Sv/Ev-derived ES cell line (Robertson, 1987) 
 
2.6 Cell culture media components  
 
Basal Iscove's Medium    Biochrom, Germany 
Dulbecco's 1X PBS with Ca & Mg ions  PAA, Germany 
Dulbecco's 1X PBS without Ca & Mg ions  PAA, Germany 
Dulbecco's Modified Eagle Medium   Merck Millipore, Germany 
EmbryoMax® 0.1% Gelatin Solution   Millipore, Germany 
ESGRO® LIF      Millipore, Germany 
Fetal calf serum (Not USA origin)   Sigma-Aldrich, Germany 
L-Glutamine 200mM (100X)    PAA, Germany 
Mitomycin-C      Calbiochem, USA 
Non-essential amino acids (100X)    Biochrom, Germany 
Penicillin/Streptomycin (100X)   PAA, Germany 
Plasmocin™      InvivoGen, USA 
Sodium pyruvate (100mM)    Biochrom, Germany 
KnockOut™ Serum replacement    Life Technologies, Germany 
β-Mercaptoethanol     Sigma-Aldrich, Germany 
 
 
2.7 Media compositions 
 
MEF Medium 
1X DMEM 
24% Heat inactivated fetal calf serum 
2mM L-Glutamine  
100µM Non-essential amino acids 
50µg/ml L- Penicillin/Streptomycin 
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MESC Medium 
1X Basal Iscove's Medium 
8% Fetal calf serum 
7.6% Heat inactivated fetal calf serum 
2mM L-Glutamine  
1mM Sodium pyruvate 
100µM Non-essential amino acids 
50µg/ml L- Penicillin/Streptomycin 
100µM β-Mercaptoethanol 
1000U/ml ESGRO® LIF 
2.5µg/ml Plasmocin™ 
  Knock out serum medium 
1X Basal Iscove's Medium 
18.9% KnockOut™ Serum replacement 
2mM L-Glutamine  
1mM Sodium pyruvate 
100µM Non-essential amino acids 
100µM β-Mercaptoethanol 
50µg/ml Penicillin/Streptomycin 
  MESC differentiation  medium: 
1X Basal Iscove's Medium 
15.6% Fetal calf serum 
2mM L-Glutamine  
1mM Sodium pyruvate 
100µM Non-essential amino acids 
100µM β-Mercaptoethanol 
50µg/ml Penicillin/Streptomycin 
  Serum free medium: 
1X Basal Iscove's Medium 
2mM L-Glutamine  
1mM Sodium pyruvate 
100µM Non-essential amino acids 
100µM β-Mercaptoethanol 
50µg/ml Penicillin/Streptomycin 
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Freezing medium 
72% MESC Medium 
20% Heat inactivated fetal calf serum 
8% Dimethyl sulfoxide 
  Fibrin matrix solution:  
1X PBS with Ca & Mg 
1.8mg/ml Fibrinogen   
200U/ml Aprotinin 
  Thrombin solution: 
1X PBS with Ca & Mg 
0.65U/ml Thrombin 
  Collagenase solution: 
1X PBS 
1% Collagenase B (w/v) 
 
2.8 Chemicals  
Ammonium bicarbonate    Sigma-Aldrich, Germany 
Copper sulphate    Sigma-Aldrich, Germany   
Disodium hydrogen phosphate  Roth, Germany 
Folin-Ciocalteu phenol reagent  Sigma-Aldrich, Germany 
Luminol     Sigma-Aldrich, Germany 
Methyl cellulose    Sigma-Aldrich, Germany 
Monopotassium phosphate   Roth, Germany 
Paraformaldehyde    Roth, Germany 
p-Coumaric acid    Sigma-Aldrich, Germany 
Ponceau S     AppliChem, Germany 
Potassium chloride    Roth, Germany 
Sodium carbonate    Roth, Germany 
Sodium chloride    Roth, Germany 
Sodium deoxycholate    Sigma-Aldrich, Germany 
Sodium dodecyl sulfate    Roth, Germany 
Sodium hydroxide    Roth, Germany 
Sodium potassium tartrate   Merck, Germany 
Tris      Roth, Germany 
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2.9 Solutions  
Ethanol      Roth, Germany 
Dimethyl sulfoxide     Merck, Germany 
Fluoromount-G     Southern Biotech, USA 
Folin - Ciocalteau reagent     Sigma-Aldrich, Germany 
Hydrogen peroxide Solution (30%)   Sigma-Aldrich, Germany 
Methanol      Roth, Germany 
Nonidet P-40      AppliChem, Germany 
Novex Sharp Pre-Stained Protein standard  Life Technologies, Germany 
NUPAGE® Antioxidant    Life Technologies, Germany  
NUPAGE® LDS Sample buffer (4X)   Life Technologies, Germany  
NUPAGE® MOPS SDS Running Buffer (20X) Life Technologies, Germany 
NUPAGE® MOPS SDS Running Buffer  Life Technologies, Germany 
NUPAGE® Reducing Agent (10X)   Life Technologies, Germany  
NUPAGE® Transfer Buffer (20X)   Life Technologies, Germany 
Restore Western Blot Stripping buffer  Thermo Fisher Scientific, Germany 
Sigmacote      Sigma-Aldrich, Germany 
Triton X-100      Sigma-Aldrich, Germany  
Tween-20      Sigma-Aldrich, Germany 
 
 
2.10 Buffer compositions 
Lowry Solution 
Solution A, Solution B, Solution C mixed in the ratio 100:1:1 
Solution A: 2% Sodium carbonate (w/v) in 0.1N Sodium hydroxide solution 
Solution B: 1.25 % Copper sulphate (w/v) 
Solution C: 3.37 % Sodium potassium tartrate (w/v) 
 
RIPA buffer 
50mM  Tris pH 7.4 
150mM  Sodium chloride 
1% Nonidet P-40 (v/v) 
0.01% Sodium dodecyl sulfate (w/v) 
0.05% Sodium deoxycholate (w/v) 
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Protein extraction buffer 
1X  RIPA buffer 
1X  Protease inhibitor cocktail  
  
Phospho-protein extraction buffer 
1X  RIPA buffer 
1X Protease inhibitor cocktail  
1X  Phosphatase inhibitor cocktail 3 
  
Ponceau staining solution 
0.01% Ponceau S (w/v)  
5% Acetic acid (v/v) 
  
Blotting buffer 
1X  NUPAGE® Transfer buffer 
0.01% NUPAGE® Antioxidant (v/v) 
20% Methanol 
  
IX Tris buffered  saline ( 1XTBS) pH 7.4 
50mM  Tris 
150mM  Sodium chloride 
  
Membrane washing solution (1X TBST) 
1X  TBS 
0.05% Tween 20 
  
Membrane blocking Solution (5%BSA) 
1X  TBST 
5% BSA (w/v) 
  
1X Phosphate buffered saline (1XPBS) 
137mM  Sodium chloride 
2.7mM  Potassium chloride 
8mM  Disodium hydrogen phosphate 
2mM  Monopotassium phosphate 
  
Permeabilisation Buffer for IF (1% PBST) 
1X PBS 
1% Triton X-100  
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Blocking buffer for IF (10%BSA) 
1X PBST 
10% BSA (w/v)  
  
Washing solution for IF (0.01% PBST) 
1X PBS 
0.01% Triton X-100  
  
Paraformaldehyde fixing solution 
1X PBS  
4% PFA (w/v)  
  
ECL detection substrate 
625µM  Luminol 
450µM  Cumaric acid 
0.03% Hydrogen Peroxide Solution (30%) (v/v) 
100mM  Tris HCl  
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2.11 Antibodies 
 
For α2m and its receptors 
Mouse anti-α2 macroglobulin antibody  Abcam, Cambridge, UK (Cat no. ab52651) 
Rabbit anti-LRP1 antibody   Abcam, Cambridge, UK (Cat no. ab92544) 
Rabbit anti-GRP78 antibody   Abcam, Cambridge, UK (Cat no. ab21685) 
 
For endothelial markers 
Rat anti-PECAM-1 antibody   Millipore, Germany (Cat no. CBL1337) 
Rabbit anti-VE Cadherin antibody  Abcam, Cambridge, UK (Cat no. ab33168) 
Rat anti-CD144 antibody   BD Biosciences, USA (Cat no. 555289)  
Rabbit anti-VEGF Receptor 2 antibody Cell Signaling Technology, USA  
(Cat no.2479) 
Rat anti-Eph receptor B4 antibody Abcam, Cambridge, UK  
(Cat no. ab106130) 
Rabbit anti-Ephrin-B2 Antibody Santa Cruz Biotechnology, USA  
(Cat no. sc1010) 
 
For mesodermal markers 
Rabbit anti-Isl1 antibody    Millipore, Germany (Cat no. AB5754) 
Rabbit anti-Brachyury antibody  Abcam, Cambridge, UK (Cat no. ab20680) 
Rabbit anti-Nkx2.5 antibody   Abcam, Cambridge, UK (Cat no. ab35842) 
Mouse anti-Smooth Muscle actin Thermo Fisher Scientific, USA  
(Cat no MS-113-P1) 
 
For growth factors 
Mouse anti-FGF-2 antibody   Millipore, Germany (Cat no. 05-118) 
Rabbit anti-VEGF165 Antibody  Millipore, Germany (Cat no. 07-1419) 
Rabbit anti-PDGF-BB Antibody,   BioVision, USA (Cat no. 5489-100) 
 
For house keeping 
Rabbit anti-GAPDH antibody   Abcam, Cambridge, UK (Cat no. ab9485) 
Mouse anti-Vinculin antibody   Sigma-Aldrich, Germany (Cat no. V9131) 
Rabbit anti β-Actin antibody Cell Signaling Technology, USA  
(Cat no.4970) 
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For phospho proteins 
Rabbit anti-p-PI3K (Tyr458/199) antibody  Cell Signaling Technology, USA  
(Cat no.4228) 
Rabbit anti-p-Akt (Ser473) antibody  Cell Signaling Technology, USA  
(Cat no.9271) 
Rabbit anti-p-p44/42 ERK1/2 antibody Cell Signaling Technology, USA  
(Cat no.9107) 
Rabbit anti-p-Stat3 (Ser727) antibody Cell Signaling Technology, USA  
(Cat no.9136) 
Rabbit anti-p-AMPKα (Thr172) antibody Cell Signaling Technology, USA  
(Cat no.2535) 
Rabbit anti-p-mTOR (Ser2448) antibody Cell Signaling Technology, USA  
(Cat no.2976) 
 
Secondary antibodies for IF 
DyLight® 650 goat anti-rat IgG  Abcam, Cambridge, UK (Cat no. ab98408) 
Alexa Fluor® 488 donkey anti-rat IgG Life Technologies, Germany  
(Cat no. A-21208) 
 
Secondary antibodies for WB 
HRP-linked donkey anti-goat IgG  Abnova, Germany (Cat no. PAB10570) 
HRP-linked goat anti-rabbit IgG  Cell Signaling Technology, USA  
(Cat no. 7074)  
HRP-linked goat anti-rat IgG   Cell Signaling Technology, USA  
(Cat no. 7077S) 
HRP-linked horse anti-mouse IgG  Cell Signaling Technology, USA  
(Cat no. 7076S) 
 
2.12 Softwares 
 
Chemicapt 500 - Western blot imaging software Peqlab Biotechnologie, Germany  
GraphPad Instat - Statistical analysis software GraphPad Software, USA 
Image J - Western blot analysis software  National Institutes of Health, USA 
Leica Application Suite Advanced Fluorescence Leica Microsystems, Germany 
Microsoft Office - Data documentation  Microsoft, USA 
Tecan Magellan™ - ELISA Software   Tecan, Switzerland   
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3. Methods 
3.1 Mouse embryonic stem cell culture 
mESCs in undifferentiated state were cultured on mitotically inactivated MEFs which 
serve as the feeder layer and with medium supplemented with LIF. The mESCs grew 
by dividing and spreading over the surface of these MEFs forming undifferentiated 
colonies. Medium was changed every 24 h with mESCs passaged every 2-3 days 
when they were semi confluent. The cell culture procedures were always performed 
under sterile conditions under the cell culture bench. The benches were always wiped 
with 70% alcohol prior to and upon completion of all culturing procedures to avoid 
contamination. The cell culture medium was also supplemented with antibiotics to 
prevent contamination. The incubator was always maintained at 37°C with humidified 
atmosphere of 5% CO2. The detailed mESC culture and maintenance procedure are 
described below. 
Thawing MEF: MEF vial was thawed two days prior to plating mESCs. The cryovial 
containing MEFs were carefully taken out from the liquid nitrogen storage tank and 
gently swirled in water bath at 37ºC to thaw for a min. When only a small ice crystal 
remained, it was removed from the water bath, wiped clean with 70% alcohol and taken 
under the cell culture bench. The vial was carefully opened, flamed and 1ml of the 
thawed cells was pipetted out very slowly into a 50ml conical tube containing 25ml 
warm MEF medium. This tube was centrifuged at 1000rpm for 5 min at RT. The 
supernatant was aspirated and pellet was resuspended in appropriate amount of warm 
MEF medium. The MEFs were plated at a density of 5 x 105 cells onto a 60mm cell 
culture dish with 5ml MEF medium. Upon adding the MEF cell suspension, the dish 
was labeled, placed in the incubator and moved in several quick back-and-forth and 
side-to-side motions to disperse the cells evenly across the cell culture plate. Since 
these MEFs were already expanded, they usually get 70% confluent after 24 h of 
plating as shown in Figure 3.1 A.  
Mitotic inactivation of MEFs: Mitomycin C was used to chemically inactivate MEF cell 
division. Treating actively dividing cells with Mitomycin C can crosslink complementary 
strands of the DNA double helix thereby inhibiting cell division. Confluent MEF culture 
dish was removed from the incubator, media aspirated and 3ml of MEF medium with 
Mitomycin C at a concentration of 10μg/ml was added and incubated for 3 hours in the 
incubator. After incubation, the dish was removed from incubator, medium aspirated 
and cells washed thrice with 3ml MEF medium to remove all traces of Mitomycin C. 
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After washing fresh 5ml MEF medium was added and placed in the incubator. This 
Mitomycin C inactivated MEF served as the template for mESCs 
 
 
 
Figure 3.1: mESC culture. A: MEF B: mESC colonies growing on mitotically inactivated MEFs. 
C:  Spinner flask rotor system D: 3-day-old EBs generated in the spinner flask system. The bar 
represents 100µm. 
 
Thawing mESCs: mESCs were thawed when the MEF dish was ensured to be 
confluent and mitotically inactivated. The MEF cell dish was removed from the 
incubator, MEF media aspirated and warm 5ml mESC medium was added prior to 
mESC plating and placed back in the incubator. The mESC cryovial was thawed similar 
to the MEF vial. The mESCs were plated at a density of 7 x 104 cells per 60mm dish 
onto the MEF cells. Upon adding the mESC suspension, the dish was moved in several 
quick back-and-forth and side-to-side motions to evenly disperse the cells across the 
cell culture dish. The dish was then labeled with the passage number and date and 
placed in the incubator.  
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Passaging and maintenance of mESCs: Confluent mESC plates were passaged 
every 2-3 days. Prior to passaging confluent and Mitomycin-inactivated MEF dish was 
ensured to be prepared as described above. For passaging, both MEF and mESC 
culture dishes were removed from the incubator. The MEF media from the MEF dish 
was aspirated, warm 5ml MESC medium was added and placed back into the 
incubator. The medium from the mESC dish was aspirated; warm 2ml trypsin was 
added to wash the cells of the medium and serum. Trypsin was immediately aspirated 
and fresh warm 2ml trypsin was added and the dish placed in the incubator to lyse the 
cells. Approximately after 30 s the both the mESC and MEF dishes were removed from 
incubator, the dislodged mESCs could be observed in the mESC dish. These 
dissociated mESCs were pipetted up and down using a 1ml pipette to get single cell 
suspension. Approx. 7 x 104 cells from this cell suspension was added to the MEF dish. 
The dish was then labeled with the passage number and date and placed into the 
incubator. After placing into the incubator, the dish was moved in several quick back-
and-forth and side-to-side motions to evenly disperse the cells across the cell culture 
dish. Fresh mESC medium was added every 24 h and dish was observed for colony 
formation under the microscope every day. Confluent mESCs are shown in Figure 3.1 
B. 
Freezing mESCs: Confluent mESC culture dish was removed from incubator and 
trypsinised with 2ml trypsin as described above for passaging. After inactivating with 
warm mESC medium, they were centrifuged at 1000rpm for 5 min. The pellet was 
resuspended in 1ml freezing medium and transferred into a cryovial. This cryovial was 
placed into Nalgene Mr. Frosty, placed in -80ºC overnight and transferred to liquid 
nitrogen tank the next day.  
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3.2 Generation of EBs  
EBs are three-dimensional aggregates of differentiating mESCs generated in 
suspension cultures. mESCs when grown in the absence of anti-differentiation factor 
LIF and feeder layer, tend to differentiate.  
Spinner flask system: Spinner flasks were used for generating EBs in suspension as 
shown in Figure 3.1 C. These flasks are fitted with hanging magnetic stirring bars. The 
inner walls of the spinner flask and the magnetic bars were coated with Sigmacote, a 
silicone solution. Sigmacote forms a thin film on glass surface. As it is water repellent it 
prevents cells from attaching to glass surface and promotes cell-cell adhesion in order 
to form 3D aggregates.  
EB generation: Sigmacote-coated and autoclaved spinner flask was ensured to be 
prepared. This spinner flask was taken into the cell culture hood and 125ml warm 
mESC differentiation medium was added. The mESC dish from which EBs were to be 
generated was taken, media aspirated and washed with warm 2ml trypsin. Fresh warm 
2ml trypsin was added and the dish placed in the incubator to lyse the cells. 
Approximately after 30 s the mESC dish was removed from incubator, the dislodged 
mESCs could be observed. These dissociated mESCs were pipetted up and down 
using a 1ml pipette to get single cell suspension. To this 8ml warm mESC media was 
added to inactivate trypsin. Approx. 1.5 to 2 x 106 cells from this cell suspension were 
added to the spinner flask containing medium. The spinner flask was labeled with the 
passage number and date and then placed into the incubator on the magnetic stirring 
plate. The flask was stirred clockwise and anti-clockwise at a speed of 20rpm. The 
following day fresh 125ml medium was added to make a total of 250ml medium. On the 
consecutive days, partial medium was changed, where 125ml medium was aspirated 
out and fresh 125ml medium was added. On the desired end day of EB formation 
usually on day 3, the spinner flask was removed from the incubator and the EBs were 
collected using a wide open 10ml pipette onto a 100mm non-adherent bacteriological 
dish, placed into the incubator on the shaker until further use. Formation of 3-day-old 
EBs is represented in Figure 3.1 D. 
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3.3 Treatment of EBs with α2m and other factors 
For each experimental sample approx. 20-25 3-day-old EBs were taken in each 60mm 
bacterial culture dish containing 5ml Knock out serum medium. Knock out serum 
medium was used to rule out the presence of α2m or any other growth factors present 
in FCS. On day 4, the EBs were treated with appropriate factors in fresh 5ml Knock out 
serum medium and the dish was placed on the shaker inside the incubator. Medium 
was changed every 24 h with fresh factors added each time. On day 9 the experiment 
was terminated with treated EBs collected for protein extraction or for 
immunofluorescence studies. The EBs were treated with the factors mentioned in 
Table 3.3 along with their concentration used for this research work. 
Factors Concentration 
α2m 4µg/ml 
RAP 10nM 
anti-LRP1 antibody 0.2µg/ml 
anti-GRP78 antibody 0.2µg/ml 
AG1296 (PDGFR inhibitor) 800nM 
SU5402 (FGFR2 inhibitor) 15µM 
SU5614 (FLK1 inhibitor) 1.5µM 
AG490 (JAK2 inhibitor) 50µM 
Compound C (AMPK inhibitor) 235nM 
LY294002 (PI3K inhibitor) 20µM 
PD98089 (ERK1/2 inhibitor) 20µM 
Wortmannin (PI3K inhibitor) 2.5µM 
 
Table 3.3: Concentrations of all α2m and other inhibitors used for experiments 
 
3.4 PECAM1/ VE-Cadherin Immunohistochemistry 
To visualize three dimensional vascular network formations, the EBs were stained for 
the endothelial markers, PECAM1 and VE-Cadherin. Vasculature could be observed in 
a differentiating EBs from day 7 onwards. For all IHC staining experiments the EBs 
were treated until day 9 of differentiation to look for well-established vascular 
structures.  
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Sample preparation: On day 9 after treatment with different factors the plates 
containing EBs were removed from the incubator and the EBs were collected into 
microcentrifuge tubes and labeled. Cell culture medium was aspirated and EBs were 
washed twice with PBS in order to remove traces of the cell culture medium. 
Fixation: Ice cold methanol was used to precipitate proteins. Methanol with a 
temperature of -20ºC was added to each of the tubes until the EBs were completely 
immersed for fixation and put at -20ºC for 30 min until further use. 
Permeabilization and blocking: After fixation EBs were washed twice with PBS and 
permeabilized using 1% PBST and placed on shaker for 15 min, consequently blocked 
with blocking buffer (10% BSA) for 1 h to block nonspecific protein binding sites. 
Antibody staining: After blocking, the EBs were washed once with 0.01% PBST and 
incubated with the primary antibody against PECAM1 or VE-Cadherin at a dilution of 
1:100 in blocking buffer for 2 h on the shaker at RT. After this they were washed three 
times with 0.01% PBST and incubated with the secondary antibody anti-rat Alexa 488 
at a dilution of 1:100 in blocking buffer for 1 h in dark on the shaker at RT. Then they 
were washed three times, 5 min each with 0.01% PBST and taken for imaging or 
stored at 4ºC until further use.  
Imaging: The stained EBs were taken, transferred onto a chamber slide and observed 
for vascularization under the Leica SP2 AOBS confocal microscope. Using 10X 
objective, Z-series images, measuring 50μm sections were taken from the top to the 
bottom of each EB that may have a diameter ranging from 600-1000μm. Around 10-15 
Z-series images were captured for each EB and then merged to obtain a single 2D 
image. This 2D image was further utilized for analysis.  
Evaluation: From the image acquired on the confocal microscope, vascularization was 
determined manually by counting the number of branching points in an EB divided by 
the total area of that EB in μm2. The area of the EB was measured using Leica LCS 
imaging software. These values were tabulated on an excel sheet and graph plotted. 
Approximately 10-15 EBs of each experimental sample were analysed. Untreated 
sample served as the control for each experiment.  
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3.5 Western blotting 
Protein extraction: RIPA buffer was used for whole cell lysate and membrane bound 
protein extraction. For total protein isolation the treated EB samples were removed from 
the incubator, cell culture media aspirated and after washing the EBs twice with cold 1X 
PBS, they were collected into a microcentrifuge tube and equal amount of ice cold 
protein extraction buffer was added and sonicated using a homogenisor for 30 s. This 
was then centrifuged at 15000rpm for 10 min at 4ºC. The supernatant containing the 
extracted protein was collected into a new microcentrifuge tube, labeled and stored at -
80ºC. Phospho-protein isolation was performed in the same manner as total protein 
extraction except that phospho-protein extraction buffer was used instead of protein 
extraction buffer. 
Quantification: Protein concentration was determined using Lowry’s method. BSA 
protein standards were prepared. 10µl of the extracted protein taken in a 
microcentrifuge tube was mixed with 700µl of Lowry Solution and incubated for 10 min 
at RT. 200µl of 1N Folin - Ciocalteau reagent solution was added and incubated for 
additional 30 min at 37ºC. This was then centrifuged at 15000rpm for 30 min at RT. The 
colorimetric absorbance was read at 578nm using ELISA reader and values were 
obtained using the Magellan software. Absorbance was plotted against the known BSA 
protein standard to obtain the calibration curve from which the unknown protein 
concentrations of all samples were determined.   
Sample preparation for gel electrophoresis: Samples for electrophoresis were 
prepared by mixing 20µg of protein sample with 1X NUPAGE® LDS Sample buffer, 1X 
NUPAGE® reducing agent and volume made up to 20µl with water. This mixture was 
heated for 10 min on the heating block at 75 ºC.   
Gel electrophoresis: Samples were loaded onto NuPAGE® 4-12% Bis-Tris precast 
gels. 3µl Novex Sharp Pre-Stained Protein standard was also loaded to one of the 
wells to determine protein size. 200ml of 1X MOPS SDS Running Buffer was added 
onto the upper buffer chamber and 300ml added to the lower buffer chamber. 500µl of 
NUPAGE® antioxidant was added to the upper buffer chamber. The electrophoresis 
apparatus was closed, connected to the power supply and run at 180V for 1 h till the 
dye reached the bottom of the gel. 
Western blotting: Blotting was performed by wet transfer method using Xcell II™ Blot 
module. Blotting sponges and filter paper were soaked in transfer buffer. The gel 
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cassette was opened and the gel was carefully removed into a tray. A sandwich was 
prepared by layering 3 blotting sponges, a filter paper, gel, nitrocellulose membrane, a 
filter paper and 3 blotting sponges. This sandwich was placed on top of the cathode 
core of the blot module and closed with the anode core. This blotting module was slid 
into the Xcell SureLock™ Mini-Cell and Blotting buffer was poured into it. The outer 
chamber was filled with 650ml water. The blotting apparatus was closed, connected to 
the power supply and run at 25V for 1 h.  
Ponceau staining: To check the success of blotted proteins on the nitrocellulose 
membrane, the membrane was incubated in Ponceau staining solution for 2 min. The 
membrane was then destained in water to visualize the resolved protein bands. 
Immuno-staining: The blotted membrane was cut based on the protein of interest 
referring to the protein standard. The membrane was blocked in membrane blocking 
solution for 1 h with agitation. After washing once with 1X TBST, the membrane was 
incubated with appropriate primary antibody diluted in 5% BSA in 1X TBST overnight at 
4ºC with agitation. The primary antibody was taken directly from the original stock 
solution as supplied from the company and diluted with the dilution factor shown in 
Table 3.5. The membrane was washed thrice with 1X TBST for 5 min and incubated 
with HRP-conjugated secondary antibody diluted in 5% BSA in 1X TBS for 1 h with 
agitation. The membrane was washed thrice with 1X TBST for 5 min each.  The 
concentrations of the primary and secondary antibodies used for staining for all the WB 
experiments are listed in Table 3.5. 
Chemiluminescence detection and imaging: The membrane was incubated for 1 min 
in ECL detection substrate and placed into the chemiluminescence imaging system. 
Using the camera fitted to this imaging system the emitted chemiluminescence was 
captured and converted this into a digital image using the Chemicapt 500 Western blot 
imaging software. 
Analysis: From the images obtained, densitometric quantification was performed using 
the ImageJ software. The final value of each band was obtained after normalizing with 
their respective loading control.  
Stripping membranes: In order to reprobe for another protein on a chemiluminescent 
membrane, the membrane was washed in 1X TBST and incubated in Restore Western 
Blot Stripping buffer for 15 min on RT, washed in 1X TBST, blocked and stained for 
primary and secondary antibody as described above. 
  
38 
 
Primary antibody  Dilution Protein size (KDa) 
Anti-alpha 2 macroglobulin antibody  1:1000 163 
Anti-LRP1 antibody 1:5000 85 
Anti-GRP78 antibody 1:2000 75 
Anti-PECAM-1 antibody 1:1000 130 
Anti-VE Cadherin antibody 1:1000 115 
Anti-VEGF Receptor 2 antibody 1:1000 230 
Anti-Isl1 antibody  1:1000 40 
Anti-Brachyury antibody 1:1000 53 
Anti-Nkx2.5 antibody 1:1000 72 
Anti-Smooth Muscle actin 1:5000 42 
Anti-FGF-2 antibody 1:1000 18 
Anti-VEGF165 Antibody 1:1000 16 
Anti-PDGF-BB Antibody,  1:500 18 
Anti β-Actin antibody 1:2000 42 
Anti-GAPDH antibody 1:2000 36 
Anti-Vinculin antibody 1:1000 117 
Anti-Phospho-PI3K (Tyr458/199) antibody  1:1000 60 & 85 
Anti-Phospho-Akt (Ser473) antibody 1:1000 60 
Anti-Phospho-p44/42 ERK1/2 antibody 1:1000 42 & 44 
Anti-Phospho-Stat3 (Ser727) antibody 1:1000 86 
Anti-Phospho-AMPKα (Thr172) antibody 1:1000 62 
Anti-Phospho-mTOR (Ser2448) antibody 1:1000 289 
 
Secondary HRP linked antibody Dilution 
HRP-linked donkey anti-goat IgG 1:1000 
HRP-linked goat anti-rabbit IgG 1:1000 
HRP-linked goat anti-rat IgG 1:1000 
HRP-linked horse anti-mouse IgG 1:1000 
 
Table 3.5: Primary antibody and secondary antibody dilution used for WB and protein 
band size observed.  
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3.6 Sprout assay  
Sprout assay is an in-vitro angiogenesis assay developed by Korff et al., 1998. It is 
based on the principle that aggregates of ECs can form capillary structures when 
embedded onto a 3D matrix that mimic in-vivo microenvironment. 5-day-old EBs were 
dissociated into single cells and spheroids of defined cell number were generated in 
methyl cellulose medium by hanging drop method. These spheroids were embedded 
onto fibrin matrix polymerised with thrombin to monitor induction or inhibition of capillary 
formation by adding α2m macroglobulin and other exogenous factors.  
Methyl cellulose stock preparation: 6g methyl cellulose was autoclaved in 500ml 
storage bottle along with a magnetic stirrer. Under the sterile bench 250ml of warm 
basal Iscove’s DMEM was added to dissolve methyl cellulose and put on the magnetic 
stirrer at 60C for 20 min. Another 250ml basal medium was added and put on the 
magnetic stirrer for 1 h at room temperature. This was then put at 4C overnight on 
stirrer to further dissolve methyl cellulose (methyl cellulose sometimes does not 
dissolve completely). This solution was aliquoted in 50ml tubes and centrifuged at 
4000g for 2 h at RT. the supernatant was transferred to a new 50ml tube and stored at 
4C till use. 
Dissociating EBs: 5-day-old EBs were removed from the incubator and placed into a 
sterile bacterial dish, washed twice with 1X PBS and warm 5ml collagenase B solution 
was added and placed on the shaker inside the incubator for 5 min.  After incubation, 
the dish was removed and using a 1ml pipette, the EBs were pipetted up and down to 
get a single cell suspension. This cell suspension was collected into a 15ml conical 
tube and warm MESC medium was added to inactivate collagenase activity. The tube 
was centrifuged at 300g for 5 min at RT to pellet the cells. The cells were resuspended 
in 10ml MESC medium and cell number determined using haemocytometer.  
Spheroid Generation by Hanging Drop Method: After determining the cell number, 
0.34 million cells were suspended in 10ml 20% methyl cellulose (v/v) in MESC medium 
to get approx. 1000cells/spheroid in every 30µl of the medium. Using a multi-channel 
pipette, several 30µl drops of this cell suspension were dispensed on to the inside of 
100mm bacterial dish lid. The bottom dish was placed onto this lid containing the many 
drops and the plate was inverted to original posture and placed into the incubator for 24 
h as hanging drops. Approx. 15-20 spheroids are generated for each experimental 
sample.   
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Spheroid collection: After 24 h, the plate was assessed under the microscope for 
well-formed spheroids. The plates were then taken under the bench, inverted and 10ml 
medium was slowly added to the inside of the lid containing spheroids. These 
spheroids were then carefully removed into a conical tube and centrifuged at 300g for 3 
min at RT to pellet the spheroids. The spheroids were then washed once in 1X PBS to 
remove traces of medium by centrifuging at 300g for 3 min at RT and re-suspended in 
1ml fresh 1X PBS.  
Spheroid embedding: 250µl of fibrin matrix solution was added to each well on a 4 
well plate. To this 50µl of spheroid suspension in PBS was added and the plate swirled 
well in order to disperse the spheroids evenly. Approx. 15-20 spheroids were ensured 
to be present in each well. To polymerize the fibrin matrix, 10µl of thrombin at a final 
concentration of 0.65 NIH U/ml was added, rapidly mixed and placed in the incubator 
for 30 min.   
Sprout stimulation with various factors: Once the fibrin matrix was polymerized, 
750µl basal MESC medium (without fetal calf serum) with appropriate stimulant was 
added to each well and placed back into the incubator. A well with no stimulant added 
served as the control. 24 h after stimulation, the plate was observed under the light 
microscope for sprout formation. Figure 3.6 represents the formation of sprouts.  
 
 
Figure 3.6: Sprout formation from 5-day-old mEB-derived spheroid within 24 h of 
embedding on fibrin matrix. The bar represents 100µm. 
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Fixation: The plate was removed from incubator; media was aspirated and washed 
once with PBS. To this cold 4% Paraformaldehyde solution was added to fix the 
sprouted spheroids. The plate was stored at 4 ºC until imaging. 
Imaging: The plate was placed under the Leica SP2 AOBS confocal microscope for 
imaging of sprouted spheroids. As observed in Figure 3.6 each spheroid could be 
observed with numerous sprouts of varying lengths originating from its surface under 
the 10X objective lens. 2D images were taken from 10-15 spheroids for each 
experimental sample. This image was further utilized for analysis. 
Analysis: The image acquired from the confocal microscope was taken for analysis. 
Using Leica LCS imaging software the sprout length of each sprout of a spheroid was 
measured in µm2. The branches in the each sprout were also measured. The 
cumulative sprout length for each spheroid was calculated. On average 10-15 
spheroids of each experimental sample were analysed. These values were tabulated 
on an Excel sheet and graph plotted. Untreated sample served as the control for each 
experiment. 
 
3.7 Statistical analysis 
Each experiment was performed minimum 3 times on independent experiments. Data 
were represented as percentage of control with percentage of standard deviation 
(%SD). Data was analysed using the statistical analysis software GraphPad Instat 
using one-way analysis of variance (ANOVA) with Tukey post-tests for multiple 
comparisons and Student’s t-test for single measurements. Differences were 
considered statistically significant when P value was calculated to be lesser than or 
equal to 0.05.  
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4. Results 
4.1 Endogenous expression of α2m and its receptors in 
differentiating mEBs 
To examine the effects of exogenous α2m on differentiating mESCs, the endogenous 
expression of α2m and both its receptors were investigated. Total protein was collected 
from EBs every alternate day from day 0 until day 10 where day 0 samples were the 
samples cultivated in the presence of LIF and are in the undifferentiated state. The 
results revealed that in undifferentiated and differentiating state mEBs expressed α2m, 
its expression was down-regulated upon differentiation (Figure 4.1). Undifferentiated 
mEBs express LRP1. During the onset of differentiation i.e. on day 2 LRP1 was down-
regulated and progressively upregulated throughout differentiation. This expression 
pattern supports previous findings that LRP1 is involved in various cell signaling 
pathway pertaining to cell proliferation and differentiation (Hennen et al., 2013). The 
relative GRP78 expression was also progressively upregulated upon differentiation 
suggesting its active role in folding and assembly of proteins in the endoplasmic 
reticulum thus sustaining homeostasis in the developing EB, as GRP78 was reported to 
be essential for pluripotent cell proliferation (Boucher et al., 2011). 
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Figure 4.1: Endogenous expression of α2m, LRP1 and GRP78 in differentiating mESCs. 
A: Western blot analysis α2m, LRP1 and GRP78 expression from day 0 until day 10 B: 
Graphical representation of the relative protein expression of A. n=3 (α2m), n=4 (LRP1), n=6 
(GRP78). *: P<0.05 
 
4.2 Enhancement of vasculogenesis in differentiating mEBs 
upon α2m treatment 
4-day-old mEBs treated for 6 days with increasing concentration of α2m ranging from 
0.5µg/ml to 6µg/ml concentration were assessed for vascularization by staining the 
mEBs against the endothelial marker, CD31/ PECAM1 which is expressed at the 
intercellular junctions of endothelial cells. The vascular network formed in the 
differentiating EBs was quantified as the number of branching points per micrometer 
square. As shown in Figure 4.2, a dose-dependent increase in vascularization with 
increasing concentrations of α2m could be observed. Maximum vascularization was 
obtained with α2m concentration of 4µg/ml. In order to reconfirm the vascularization, 
the mEBs were stained against VE-Cadherin, an endothelial intracellular junctional 
protein responsible for EC permeability. A similar increase in branching points was 
observed with 4µg/ml α2m treated mEBs.  
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Figure 4.2: Vascularization upon α2m treatment in mEBs. A: Confocal images of EBs 
stained against PECAM1 with increasing concentrations of α2m. The bar represents 100µm. B: 
Quantification of A representing the vascularization induced by α2m treatment. n=4, *: P<0.05 
C: Confocal images of EBs stained against VE-Cadherin with 4µg/ml α2m. The bar represents 
100µm. D: Quantification of C representing the vascularization induced by α2m treatment. n=4, 
*: P<0.05 
 
4.3 α2m-induced vasculogenesis upregulates expression of 
angiogenic growth factors FGF2, VEGF165 and PDGF-BB 
In order to investigate whether the vasculogenesis induced by α2m is regulated by 
angiogenic growth factors, 4-day-old EBs treated with increasing concentrations of α2m 
for 6 days were analysed for the expression of FGF2, VEGF 165 and PDGF-BB. As 
shown in Figure 4.3, the protein expression of all growth factors showed dose-
dependent increase with α2m with 4ug/ml concentration exerting maximal upregulation. 
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The relative expression of VEGF165 and FGF2 was upregulated 2.5 fold compared to 
control. Comparatively PDGF-BB expression was only slightly upregulated and could 
be attributed to the fact PDGF-BB plays active role in the remodeling of the vascular 
structure. 
 
 
Figure 4.3: Upregulation of the angiogenic growth factors FGF2, VEGF and PDGF-BB on 
α2m-induced vasculogenesis. A: Western blot analysis of FGF2, VEGF165 and PDGF-BB 
expression in mEBs treated with increasing concentrations of α2m B: Graphical representation 
of the relative protein expression of A. n=6 (FGF2), n=5 (VEGF165), n=4 (PDGF-BB), *: P<0.05. 
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4.4 Impact on the activity of LRP1 and GRP78 receptors for 
α2m- induced vasculogenesis 
To determine the impact of LRP1 and GRP78 for α2m-induced vasculogenesis, 4-day-
old EBs were treated for 6 days with antibodies against the receptors LRP1 and 
GRP78 and were analysed for vascularization by staining against PECAM1. As 
illustrated in Figure 4.4 A-D, the treatment with anti-LRP1 antibody and anti-GRP78 
antibody and co-treatment with α2m abolished vascularization observed with α2m 
alone, confirming that α2m exerts its angiogenic effects by acting on both its receptors 
LRP1 and GRP78. The protein expression of LRP1 and GRP78 receptors showed a 
dose-dependent upregulation on increasing α2m concentrations Figure 4.4 C, D.  
 
 
  
48 
 
 
 
 
 
  
49 
 
 
Figure 4.4: Impact on the activity of LRP1 and GRP78 receptors for α2m-induced 
vasculogenesis. A: Confocal images of EBs stained against PECAM1 on blocking the receptor 
LRP1 with anti-LRP1 antibody and its co treatment with α2m. The bar represents 100µm B: 
Quantification of A representing the vascularization inhibited upon anti-LRP1 treatment (n=3), *: 
P <0.05, significant compared to the untreated control; 
#
: P<0.05 significant compared to α2m 
treatment alone C: Confocal images of EBs stained against PECAM1 on blocking the receptor 
GRP78 with anti-GRP78 antibody. The bar represents 100µm D: Quantification of C 
representing the vascularization inhibited upon anti-GRP78 treatment (n=3), *: P<0.05, 
significant compared to the untreated control; 
#
: P<0.05 significant compared to α2m treatment 
alone. E: Western blot analysis of LRP1 and GRP78 expression in mEBs treated with increasing 
concentrations of α2m F: Graphical representation of the relative protein expression of A, n=3 
(LRP1), n=6 (GRP78), *: P <0.05 
 
4.5 Upregulation of endothelial and mesodermal markers on 
α2m treatment of mEBs 
Besides PECAM1 immunofluorescence studies on vascularization, protein expressions 
of PECAM1/CD31, VE-Cadherin and FLK1/VEGFR2 were analysed and a similar dose- 
dependent upregulation with increasing concentrations of α2m was observed (Figure 
4.5 A,B) which can be correlated with the expression pattern of angiogenic growth 
factors. Expression of mesodermal markers Nkx2.5, Isl1, Brachyury and αSMA 
revealed an upregulation upon 4µg/ml α2m treatment compared to control (Figure 4.5 
C,D).  
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Figure 4.5: Upregulation of endothelial and mesodermal markers on α2m treatment of 
mEBs. A: Western blot analysis of VE-Cadherin, FLK1 and CD31 expression on increasing 
concentrations of α2m. B: Graphical representation of the relative protein expression of A, n=3 
(VE-Cadherin), n=6 (FLK1), n=3 (CD31), *: P<0.05, significant as compared to untreated control 
C: Western blot analysis of Nkx2.5, Isl1, Brachyury and αSMA expression in mEBs treated with 
increasing concentrations of α2m. D: Graphical representation of the relative protein expression 
of A: n=3 (Nkx2.5), n=7 (Isl1), n=7 (Brachyury), n=8 (αSMA), *: P<0.05 significant as compared 
to untreated control.  
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4.6 LRP1 antagonist RAP abolishes α2m-induced 
vasculogenesis with down-regulation of growth factors 
RAP, an LRP1 antagonist can inhibit binding of all ligands to LRP1. In order to further 
investigate the effects of blocking LRP1, EBs were treated with RAP from day 4 
onwards for 6 days along with co treatment of α2m. This study validates the previous 
experiment with LRP1 antibody since blocking LRP1 with RAP treatment abolished 
α2m-induced vasculogenesis (Figure 4.6 A,B). For further investigations, western blot 
analysis for angiogenic growth factors FGF2, VEGF 165 and PDGF-BB was performed. 
Our experiments revealed that their increase in expression upon α2m treatment was 
blunted upon blocking the LRP1 receptor with RAP, thereby proving that growth factor 
expression is regulated downstream of the LRP1 signaling pathway (Figure 4.6 C,D).  
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Figure 4.6: RAP abolishes α2m-induced vasculogenesis with down regulation of FGF2, 
VEGF165 and PDGF-BB. A: Confocal images of EBs stained against PECAM1 on treatment 
with RAP and co-treatment with α2m. The bar represents 100µm B: Quantification of A 
representing inhibition of vascularization upon RAP treatment. n=7, *: P<0.05, 
#
: significant 
compared to α2m treatment alone with P<0.05 C: Western blot analysis of FGF2, VEGF165 and 
PDGF-BB expression in mEBs treated with RAP along and co-treatment with α2m D: Graphical 
representation of the relative protein expression of C. n=7 (FGF2), n=5 (VEGF165), n=7 (PDGF-
BB), *: P<0.05 as compared to the untreated control; #: P<0.05, significant compared to α2m 
treatment alone.  
 
4.7 Inhibitors of VEGFR2 and PDGFR abolish α2m-induced 
vasculogenesis 
To investigate further the downstream signaling pathways of LRP1 activation, the 
growth factor receptors VEGFR2 and PDGFRβ were blocked with SU5614 and 
AG1296 respectively and assessed for vascularization by staining against PECAM1. 
EBs were treated with either 1.5µM SU5614 or 800nM AG1296 for 6 days along with co 
treatment of α2m from day 4 onwards. It was observed that blocking the receptors 
alone or with co treatment of α2m inhibited vasculogenesis suggesting that α2m is 
activating VEGFR2 as well as PDGF mediated signaling pathways (Figure 4.7). 
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Figure 4.7: Inhibitors of VEGFR2 and PDGFR abolish α2m-induced vasculogenesis. A: 
Confocal images of EBs stained against PECAM1 on blocking VEGFR2 with 1.5µM SU5614 in 
either presence or absence of α2m. B: Quantification of A representing the vascularization 
inhibited with SU5614 (n=3), *: P<0.05, significant compared to the untreated control; 
#
: P<0.05, 
significant compared to α2m treatment alone C: Confocal images of EBs stained against 
PECAM1 on blocking PDGFR (α and β) with 800nM AG1296 in either presence or absence of 
α2m. D: Quantification of C representing the vascularization inhibited with AG1296 (n=3), *: 
P<0.05, significant compared to the untreated control; 
#
: P<0.05, significant compared to α2m 
treatment alone. The bar represents 100µm. 
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4.8 Inhibiting FGFR, VEGFR2 and PDGFR down-regulates α2m-
mediated VE-Cadherin, VEGF165 and PDGF-BB expression 
Blocking the receptors of VEGF165 and PDGF-BB blunted vasculogenesis inhibiting 
downstream angiogenic signaling cascades. The expression of the growth factors 
FGF2, VEGF165 and PDGF-BB and endothelial marker VE-Cadherin were investigated 
upon blocking the receptors for FGF2, VEGF165 and PDGF-BB with 15µM SU5402, 
1.5µM SU5614 and 800nM AG1296, respectively. Upon treatment of 4-day-old EBs 
with these inhibitors alone and in combination with α2m for 6 days the expression of 
growth factors and VE-Cadherin was abolished as analysed using western blot 
technique (Figure 4.8). It was also revealed that blocking VEGFR2 and PDGFRs, did 
not abolish FGF2 expression, but blocking FGF2 receptor decreased the expression of 
both VEGF165 and PDGF-BB suggesting the activation of VEGF and PDGF signaling 
to be down-stream of FGF signaling. Furthermore the angiogenic differentiation 
occurred only after the activation of growth factor signaling as revealed by expression 
analysis of VE-Cadherin. 
.  
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Figure 4.8: Blocking growth factor receptors down regulates expression of VE-
Cadherin, FGF2, VEGF165 and PDGF-BB. A: western blot analysis of VE-Cadherin, 
FGF2, VEGF165 and PDGF-BB expression in mEBs treated with either 15µM SU5402 
(FGF2R inhibitor), 1.5µM SU5614 (VEGFR2 inhibitor) and 800nM AG1296 (PDGFR 
inhibitor) alone or in combination with α2m. B: Graphical representation of the relative 
protein expression of A, n=6 (VE-Cadherin) n=7 (FGF2), n=6 (VEGF165), n=5 (PDGF-
BB), *: P<0.05, significant to the untreated control; #: P<0.05 significant compared to 
α2m treatment alone. 
 
4.9 Activation of ERK1/2, PI3K, AKT, AMPK and STAT3 upon 
treatment of mEBs with α2m 
To further elucidate the signaling pathways involved in α2m-induced vasculogenesis, 
the immediate effects of α2m on phosphorylation of various signaling proteins were 
analysed. To achieve this aim 5-day-old EBs were treated with α2m and proteins were 
collected at intervals of 5, 15, 30, 60 and 120 min and analysed by western blot for 
protein phosphorylation. As shown in Figure 4.9 A, B administration of α2m activated 
ERK1/2, PI3K, AKT and STAT3 in EBs with maximum activation achieved after 30min. 
ERK1/2 functions in cellular proliferation, differentiation, and survival (Roskoski 2012). 
The phosphorylation of STAT3 indicates activation in transcription playing a role in cell 
proliferation, differentiation and migration (Teng et al., 2009). Activation of PI3K and its 
downstream activator AKT suggests involvement of α2m in the regulation of cell 
growth, survival, and proliferation. Figure 4.9 C, D illustrates that AMPKα was activated 
upon α2m indicating the need for energy in the cells to drive endothelial differentiation 
programs as AMPKα was reported to be activated under hypoxic conditions on 
endothelial cells promoting angiogenesis (Ouchi et al 2005). The downstream effector 
of AMPK, mTOR was observed to be inhibited. 
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Figure 4.9: Protein phosphorylation upon α2m. A: Western blot analysis of phosphorylation 
of ERK1/2, PI3K, AKT and STAT3 B: Graphical representation of A p-PI3K (n=6), p-ERK1/2 
(n=3), p-AKT (n=5), p-STAT3 (n=5), C: Western blot analysis of phosphorylation of AMPK and 
mTOR. D: Graphical representation of C with p-AMPK (n=5) and p-mTOR (n=5) *: P<0.05, 
significant as compared to the untreated control. 
 
4.10 Inhibition of signaling cascades blocks α2m-induced 
vasculogenesis 
Administration of α2m on mEBs activated ERK1/2, PI3K, AKT, STAT3 and AMPK. To 
investigate further the downstream targets in the α2m-induced vasculogenesis, these 
phospho-proteins were blocked with their respective inhibitors and EBs were assessed 
for vascularization. The 4-day-old EBs were treated either with 50µM AG490 (JAK2 
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inhibitor), 235nM Compound C (AMPK inhibitor), 20µM PD98059 (ERK1/2 inhibitor), 
2.5µM Wortmannin (PI3K inhibitor) alone or in combination with α2m and 
vascularization determined by staining against PECAM1. As represented in Figure 
4.10, the treatment with inhibitors against the phospho-proteins attenuated endothelial 
differentiation leading to abolishment of vascularization, suggesting activation of 
phospho-proteins downstream of the LRP1 signaling cascade. This experiment also 
signifies the importance of ERK1/2, PI3K, STAT3 and AMPK in modulating and 
inducing differentiation programs within mEBs. 
 
Figure 4.10: Inhibiting protein phosphorylation of signaling molecules blocks α2m-
induced vasculogenesis. A: Confocal images of EBs stained against PECAM1 under AG490 
(JAK2 inhibitor), Compound C (AMPK inhibitor), PD98089 (ERK1/2 inhibitor), Wortmannin (PI3K 
inhibitor) and cotreatment with α2m. The bar represents 100µm. B: Quantification of A 
representing abolishment of vascularization upon inhibition of JAK2, AMPK, ERK1/2 and PI3K 
protein phosphorylation with their respective inhibitors. n=3, *, P<0.05, significant compared to 
the untreated control; 
#
: P<0.05, significant compared to α2m treatment alone.  
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4.11 Inhibiting growth factors blocks ERK1/2 phosphorylation 
To understand the relation among upregulation of angiogenic growth factors and 
protein phosphorylation of signaling proteins in α2m-induced vasculogenesis,  5-day-
old EBs were incubated either with 15µM SU5402 (FGF2R inhibitor), 1.5µM SU5614 
(VEGFR2 inhibitor) and 800nM AG1296 (PDGFR inhibitor) alone or in combination with 
α2m for 60 min and protein extracted. As shown in Figure 4.11 phosphorylation of 
ERK1/2 was inhibited upon blocking the angiogenic growth factor receptors, suggesting 
the signal transduction pathways induced by growth factors and pERK1/2 activation are 
interconnected and are modulated by each other. 
 
 
Figure 4.11: Blocking growth factor receptors inhibits ERK1/2 phosphorylation. A: 
western blot analysis of ERK1/2 phosphorylation in EBs treated either with SU5402, SU5614, 
AG1296 or with α2m. B: Graphical representation of the relative protein expression of A, n=4 *: 
P<0.05, significant compared to the untreated control; 
#
: P< 0.05, significant compared to α2m 
treatment alone.  
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4.12 Functional assay of α2m-induced vasculogenesis 
Endothelial cell proliferation, migration and tube formation are central to angiogenesis. 
In this experiment sprouting assay was performed which aims to measure the 
outgrowth of endothelial cell structures from EBs. Here spheroids were derived from 5-
day-old mEB and embedded onto fibrin matrix which was polymerized using thrombin. 
Subsequently sprout formation was assessed by light microscopy. As shown in Figure 
4.12, spheroids treated with α2m produced longer sprouts and individual sprouts 
showed increased branching compared to the untreated control. Spheroids treated with 
10ng/ml FGF2 served as positive control.  
 
 
 
 
Figure 4.12: Sprout assay of MESC spheroids upon α2m treatment. A: Sprouting of mESC 
spheroids upon α2m and bFGF. The bar represents 100µm. B: Graphical representation of A 
with n=5 *: P<0.05, significant compared to the untreated control.  
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4.13 Treatment of mEBs with TNFα induces vasculogenesis 
with upregulation of α2m and LRP1 
TNFα is an inflammatory cytokine that can stimulate an acute phase reaction. 
Stimulating an acute phase reaction in mEBs theoretically should induce an 
upregulation of α2m as it is considered to be an acute phase protein. To investigate the 
regulation of α2m under inflammatory conditions in mEBs, 4-day-old mEBs were 
subjected to increasing concentrations of TNFα ranging from 10ng/ml to 100ng/ml for 6 
days. Subsequently proteins were extracted and analysed for the expression of α2m 
and its receptor LRP1.  As illustrated in Figure 4.13 A, B the protein expression of α2m 
along with its receptor LRP1 was increased 2-fold suggesting that α2m gets 
upregulated even in early developmental stages of a differentiating mEB under 
inflammatory conditions exerting its acute phase protein property. Besides triggering 
inflammatory signaling cascades, TNFα may be also implicated in angiogenesis. In 
order to study the angiogenic effects of TNFα the same samples were examined for 
vascularization by staining the EBs against PECAM1. As observed in Figure 4.13 C, D, 
TNFα increased vascularization in mEBs from 40ng/ml to 100ng/ml. 
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Figure 4.13: Treatment of mEBs with TNFα induces vasculogenesis with upregulation of 
α2m and LRP1 protein expression. A: Confocal images of EBs stained against PECAM1 
upon treatment with TNFα. The bar represents 100µm B: Quantification of A representing the 
vascularization upon increasing concentrations of TNFα (n=4). *: P<0.05, significant to the 
untreated control. C: Western blot analysis of α2m and LRP1 expression in mEBs treated with 
increasing concentrations of TNFα D: Graphical representation of the relative protein expression 
of C, α2m (n=3), LRP1 (n=3). *: P<0.05, significant compared to the untreated control. 
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4.14 Antibody blocking against LRP1 receptor impairs TNFα- 
induced vasculogenesis 
To determine if the receptor LRP1 is involved in TNFα-induced vasculogenesis 4-day-
old mEBs were treated for 6 days with TNFα (40ng/ml), TNFα (40ng/ml) plus LRP1 
antibody (0.2µg/ml)  and LRP1 antibody (0.2µg/ml) alone and were assessed for 
vascularization. As illustrated in Figure 4.14, vascularization induced by TNFα in mEBs 
was abolished upon blocking the LRP1 receptor suggesting LRP1 to be involved in the 
modulation of TNFα-induced vascularization.  
 
Figure 4.14: Antibody blocking against LRP1 receptor blocks TNFα-induced 
vasculogenesis A: Confocal images of EBs stained against PECAM1 upon treatment with 
TNFα and on blocking the receptor LRP1 with anti-LRP1 antibody upon co-treatment with TNFα. 
The bar represents 100µm B: Quantification of A representing the impairment of vascularization 
upon blocking LRP1 receptor (n=3). *: P<0.001, significant compared to the untreated control; 
#
: 
P<0.001 significant compared to TNFα treatment alone.  
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4.15 α2m dose-dependently down-regulates endogenous 
expression of TNFα in differentiating mESCs  
To investigate the regulatory mechanism of α2m on the endogenous expression of 
TNFα, 4-day-old mEBs treated for 6 days with increasing concentrations of α2m 
ranging from 0.5µg/ml to 6µg/ml were assessed for the endogenous protein expression 
of TNFα. The endogenous expression of TNFα was observed to be dose-dependently 
down regulated as illustrated in Figure 4.15, suggesting α2m may exert anti-
inflammatory effects by clearing TNFα. 
 
 
 
Figure 4.15: α2m down-regulates endogenous TNFα expression in mEBs A: Western blot 
analysis of TNFα expression in mEBs upon increasing concentrations of α2m B: Graphical 
representation of the relative protein expression of A, n=4 *: P<0.05, significant as compared to 
the untreated control.  
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5. Discussion 
The vascular system consists of the body’s network of blood vessels that include 
arteries, veins and capillaries. Vascular diseases like atherosclerosis are caused due to 
obstruction in the blood vessels which lead to ischemia and consequently myocardial 
infarction. Under such conditions, replacement of the damaged blood vessel can 
restore blood flow and improve the diseased state.  Vascular tissue engineering can 
address this challenge by regeneration of blood vessels, vascular tissue 
transplantation, stem cell technology etc. All these processes require generation of new 
blood vessels where angiogenesis is a critical step. Understanding vascular 
regeneration or repair mechanisms will enable the development of new strategies for 
innovative therapies. 
Release of acute phase proteins is a defense mechanism as to how the body reacts in 
getting back to normal homeostasis after infection, tissue injury, inflammation, trauma 
or immunological disorders. At the site of the injury, local inflammatory cells release 
pro-inflammatory cytokines like interleukins: IL-1, IL-6 and IL-8 and TNF-α, this release 
in turn further activates the production of more cytokines and inflammatory mediators 
which diffuse into the extracellular fluid compartment and circulate in the blood (Gruys 
et al., 2005). One such acute phase protein is the plasma protein α2m which is 
released by the liver during inflammatory conditions and functions mainly in the 
clearance of proteases by binding to them and in their subsequent elimination. Besides 
protease clearance, α2m functions in transportation and clearance of cytokines, 
protection against toxic cytokines, protection of cytokines against degradation and 
targeting the cytokines to cells expressing LRP1 or GRP78 receptors for induction of 
various cell signaling pathways (Esadeg et al., 2003).  
In adult tissues, a cardiac specific α2m has also been reported to be an early marker in 
cardiac hypertrophy in humans, but its physiological function is obscure (Annapoorani 
et al., 2006). Our previous study also reported α2m to induce hypertrophy in rat 
ventricular cardiomyocytes activating ERK1/2 and PI3K/Akt signaling cascades along 
with improvement in cardiac cell function (Padmasekar et al., 2007). Moreover, α2m 
was detected to be highly elevated in rats following induction of thermal injury 
(Kataranovski et al., 1999) and accumulation of α2m in wounds and skin burns has also 
been reported (Oehmichen et al., 1989, Grinnell et al., 1998), suggesting α2m could be 
involved in healing or repairing programs thereby restoring homeostasis. Interestingly, 
characterization of in-vitro cultured cord blood derived CD34+ cells differentiated into 
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early EPCs revealed upregulation of α2m suggesting its role in endothelial cell 
maturation (Ahrens et al., 2011).  
 
5.1 Induction of vasculogenesis by α2m:  
Vasculogenesis begins with the process of angioblasts forming a primitive vascular 
network through the action of FGFs. The assembly of this primordial vascular structure 
is then mediated by the action of VEGFs. The further transition from vasculogenesis to 
angiogenesis is the result of the activation of FGF and VEGF receptors (Wang et al. 
2010). The cell adhesion molecules, VE-Cadherin and PECAM1 are further involved in 
the subsequent endothelial cell differentiation (Risau et al., 1995).  
In this study, administration of native α2m to 3-day-old differentiating mEBs for 6 days 
stimulated endothelial differentiation programs leading to increased vascularization in 
the developing EB. The EB system enables investigation of vasculogenesis virtually as 
it occurs in vivo. EBs were stained against PECAM1 for quantification of vascularization 
and the increase in branching points was evaluated.  
α2m is known to bind to two receptors LRP1 and GRP78. Homozygous LRP1 KO in 
mouse leads to mortality, likewise homozygous GRP78 KO die at peri-implantation site 
suggesting both these receptors are very critical during embryonic development (Herz 
et al., 1992, Luo et al., 2006). LRP1 is involved in various cellular processes that 
involves cell signaling, lipid homeostasis and  anti-inflammation whereas GRP78 is 
highly expressed in tumor cells and is implicated in tumor cell proliferation, protection 
against apoptosis, and promotion of tumor angiogenesis (Dong et al 2008). In this 
study both LRP1 and GRP78 were found to be highly expressed in differentiating mEBs 
with their expression upregulated steadily until day 10 of differentiation. The expression 
pattern of LRP1 was distinct as it was down-regulated and re-expressed at day-2 of 
differentiation where vasculogenesis/angiogenesis begins to mEBs suggesting its 
active role in this process.   
In contrast, the expression of intrinsic α2m was observed to be down-regulated 
throughout differentiation. The treatment with α2m could be responsible for the 
additional activation of the receptors LRP1 and GRP78 which resulted in the 
enhancement of vascularization. The expression of LRP1 and GRP78 was also dose-
dependently upregulated upon α2m treatment. Moreover, blocking the receptors LRP1 
and GRP78 with their respective antibodies abolished vascularization which suggests 
that these receptors are crucial for the development of the EB. Additionally, the 
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treatment with RAP, an LRP1 antagonist also provided identical results in the 
abolishment of vascularization induced by α2m. Thus our data suggested that the 
effects of α2m on vascularization of EBs followed signaling pathways in sequence of 
LRP1 and GRP78 receptor activation.  
α2m stimulated a dose-dependent increase in vasculogenesis accompanied by a 
similar dose-dependent upregulation in protein expression of angiogenic growth 
factors, i.e. FGF2, VEGF165 and PDGF-BB as well as  endothelial markers, i.e. 
PECAM1, VE-Cadherin and FLK1. 
A strong upregulation in FGF2 was observed upon α2m treatment which suggests a 
pronounced induction of angioblasts from the mesodermal cells in the differentiating 
EB. The isoform of VEGF-A, VEGF165 was also equally upregulated confirming 
activation of endothelial differentiation pathways. VEGF165 binding to its receptor 
VEGFR2/FLK1 results in receptor kinase activity, auto-phosphorylation and activates its 
downstream signaling cascades.  VEGFR2 plays a major role in EC differentiation, 
migration, proliferation and survival (Patel-Hett et al., 2011). PDGF is involved in vessel 
maturation by recruiting pericytes. PDGF-BB is secreted by proliferating ECs and 
undifferentiated mesenchymal cells expressing its receptor PDGFRβ are recruited to 
form pericytes and SMCs (Wijk et al., 2013). In this study PDGF-BB was upregulated 
upon α2m further confirming the activity of angiogenic growth factors in α2m-induced 
vasculogenesis. 
FLK1 expressing cells can differentiate into both endothelial and mural cells. The VEGF 
stimulates endothelial cell differentiation and PDGF-BB stimulates mural cells which are 
pericytes and smooth muscle cells. Further the activation of PDGFRβ results in the 
growth and migration of these pericytes, which along with ECs form vessel-like three-
dimensional vascular network (Yamashita et al., 2000). In this study FLK1 expression 
was strongly upregulated which suggests that α2m stimulated vascularization through 
the differentiation of FLK1 expressing cells.  FLK1 is highly expressed in tip cells and 
stalk cells that are responsible in branching of vessels (Gerhardt et al., 2003). The 
protein expression of mesodermal lineage markers Nkx2.5, Isl1 and Brachyury was 
also upregulated which indicates that α2m initiated differentiation programs for 
endothelial progenitor cells rather than the proliferation of mature endothelial cell. 
Surprisingly the expression of αSMA, the major component of SMCs was down-
regulated suggesting the tunica media of the blood vessels specifically arterial vessels 
lacks SMCs which could lead to loss of contractility of the vessels (Hinz et al., 2001).   
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The expression of the angiogenic growth factors was abolished when treated with RAP 
suggesting LRP1 receptor activation in the induction of FGF2, VEGF165 and PDGF-
BB. The involvement of the GRP78 receptor in the stimulation of these growth factors 
still needs to be investigated. Blocking the receptors of VEGF165 and PDGF-BB with 
SU5614 and AG1296 respectively, abolished vascularization in mEBs, signifying the 
importance of these growth factors in the endogenous vascularization process. 
Blocking FGF2 receptor with SU5402 also abolished vascularization which was shown 
in our previous study (Sauer et al., 2013). Additionally, blocking FGF2 receptor with 
SU5402 down-regulated expression of VEGF165 and PDGF-BB suggesting, FGF2-
signaling to be upstream of VEGF and PDGF-signaling pathways in the induction of 
vasculogenesis. Thus, α2m stimulated LRP1 and GRP78 in the upregulation of 
angiogenic growth factors that led to increase in the vascularization. 
PI3K/AKT pathway is involved in a number of cellular functions like proliferation, 
adhesion, migration, metabolism and survival (Bader et al., 2005). The inactivation of 
the p110α subunit of PI3K led to embryonic lethality with severe defects in angiogenic 
sprouting and vascular remodeling which implies that PI3K pathway plays a key role in 
the normal development of blood vessels and moreover PI3K also regulates EC 
migration (Graupera et al., 2008). In this study administration of α2m on mEBs 
stimulated this pathway as PI3K/AKT was observed to be activated.  
Previous studies have demonstrated that ERK1/2 is involved in numerous signaling 
pathways that regulate survival, proliferation, migration, metabolism, differentiation and 
transcription; furthermore it has been shown that vasculogenesis of ES cells can be 
efficiently inhibited by ERK1/2 antagonists (Na et al., 2010). ERK1/2 was shown to be 
activated upon α2m. This activation in ERK1/2 was strongly abolished in presence of 
SU5402 (FGF2R inhibitor), SU5614 (VEGFR2 inhibitor) and AG1296 (PDGFR inhibitor) 
which suggest this signaling to be interconnected with growth factor activation in the 
modulation of vasculogenesis which needs to be further elucidated.  
α2m activated STAT3, a pathway involved in gene transcription in response to 
cytokines and growth factor stimulation. It is known to play an important role at the 
transcriptional level in angiogenesis besides cell survival, proliferation, differentiation, 
and onco-genesis (Chen et al., 2008). Studies have shown that VEGF upregulation is a 
result of STAT3 activation with STAT3 binding to the promoter region of VEGF resulting 
in its transcription (Niu et al., 2002).  
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The metabolite-sensing protein kinase, AMPK was observed to be activated upon α2m 
administration indicating the need for energy requirement to drive differentiation 
programs. AMPK gets activated upon sensing a decrease in ATP levels where it drives 
β-oxidation of fatty acid promoting ATP production. AMPK has been implicated as a 
regulator in angiogenesis required for migration and differentiation under hypoxic 
condition (Nagata et. al 2003).  
The downstream target of AMPK is mTOR which is a central controller of cell growth 
and proliferation by regulating protein synthesis and transcription (Hay et al., 2004). 
Upon sensing ATP deprivation, AMPK gets activated to phosphorylate effectors that 
inhibit mTOR activity (Hay et al., 2004). In this study a similar effect has been shown 
where upon activation of AMPK, an opposite inactivation of mTOR is observed upon 
α2m treatment. This suggests that mTOR may repress autophagy in order to sustain 
protein synthesis and energy production.   
Treating mEBs with PD98089 (ERK1/2 inhibitor), Wortmannin (PI3K inhibitor), AG490 
(JAK2 inhibitor) and Compound C (AMPK inhibitor) alone completely abolished 
vascularization. In combination with α2m these inhibitors significantly reduced the 
stimulation of vascularization observed upon treatment with α2m alone. This study 
proves that these signaling cascades are also intrinsically involved in vasculogenesis 
pathways.  
eNOS plays a critical role in angiogenesis and vascular permeability through VEGF 
mediated stimulation (Fukumura et al., 2001). In our previous study we have reported 
activation of eNOS along with NO generation upon α2m treatment in mEBs in 
stimulating vascularization (Sauer et al., 2013). These findings further prove the 
angiogenic potential of α2m in the differentiating mEBs.  
An in-vitro sprout formation assay was performed to test the efficacy of α2m to mediate 
vascular outgrowth. Aggregates of single celled mESCs were made to form spheroids 
by hanging drop method. These mESC-spheroids embedded onto fibrin matrix and 
treated with α2m exhibited increased sprout length compared to the untreated control 
sample. Pronounced vascular outgrowth was observed in mESC-spheroids treated with 
FGF2 alone which served as positive control. Interestingly, in the mESC-spheroids 
treated with α2m, individual vascular sprouts were branched which complements the 
α2m-induced vascularization in mEB and suggests that α2m could be specifically 
activating the tip and stalk cells. This study thereby confirms the angiogenic role of α2m 
in inducing vasculogenesis playing role in migration, proliferation and tube formation.  
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Taken together α2m activates various signaling cascades within the mEB by directing 
differentiation towards the endothelial lineage acting through LRP1 and GRP78 
signaling pathways. Figure 5.1 illustrates the activity of α2m in the enhancement of 
vascularization in differentiating mEB. 
The physiological function of the acute phase protein α2m is still very obscure. It is 
known that its plasma concentration increases upon various challenges occurring in 
adult organisms and that this property can be utilized as a possible biomarker for 
different diseases. In our study, α2m is shown to play a role in endothelial 
differentiation in early developmental stages of mouse. This angiogenic potential of 
α2m could be utilized for therapeutic purposes involving stem cell technologies in 
vascular injuries. 
The exact mechanism as to how native α2m gets activated and induces 
vasculogenesis of mESCs is yet to be determined. It might be hypothesized that the 
administered native α2m gets activated by endogenous proteases or nucleophiles that 
are produced by the differentiating mEBs. The activated α2m could then bind to LRP1 
and GRP78 mediating stimulation of vascular differentiation pathways. Further studies 
have to be performed to investigate the underlying mechanism for this activation of 
native α2m, about the oxidation state of α2m and the growth factors that could be 
bound to α2m in triggering this differentiation. It is clear that α2m binds to both the 
receptors GRP78 and LRP1 but the further downstream signaling targets of GRP78 
and if any interaction among GRP78 and LRP1 also needs to be investigated. 
5.2 Interaction of α2m and TNFα in induction of vasculogenesis:  
TNFα was identified due to its anti-angiogenic property but it was also reported to exert  
pro-angiogenic activity since injection of TNFα in rabbit corneas induced 
neovascularization (Fràter-Schröder et al., 1987, Rosenbaum et al., 1987). Moreover 
subcutaneous implantation of a pellet containing TNFα stimulated angiogenesis in mice 
(Fajardo et al., 1992). The angiogenic activity of TNFα could be attributed to its 
activation of NFκB and MAPK signaling cascades with stimulation of angiogenic growth 
factors. In response to TNFα vascular ECs have shown to initiate pro-inflammatory 
pathways leading to leukocyte adhesion, trans-endothelial migration and vascular leak 
promoting thrombosis (Bradley 2008).  
Various studies have reported the interaction of eNOS and TNFα. TNFα induced cell 
death was prevented by endogenous production of NO upon activation of eNOS in 
HeLa cells (Bulotta et al., 2001, Barsacchi et al., 2003). In another study, in human ECs 
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Figure 5.1: Schematic representation of α2m triggering vasculogenesis in mEBs 
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TNFα activated eNOS and produced NO through the AKT pathway which resulted in 
the inhibition of adhesion molecules to the endothelium. eNOS KO mouse, under 
inflammatory stimuli, displayed poor wound healing with high susceptibility to 
inflammation. These results suggest a significant anti-inflammatory role of eNOS in 
TNFα activity (De Palma et al., 2006). 
We hypothesized, since α2m is an acute phase protein, that induction of inflammation 
in mEB could stimulate its expression. Inflammation in mEB could be stimulated upon 
treatment with TNFα. To test this hypothesis, mEBs treated with varying concentrations 
of TNFα resulted in strong increase of α2m protein expression along with its receptor 
LRP1. Surprisingly the EBs did not undergo apoptosis under the effect of TNFα but 
survived. It could be hypothesized that TNFα triggered pro-inflammatory cues which 
resulted in the up-regulation of α2m. This study also signifies the acute phase property 
and protective role of α2m even in early developmental stages of mouse embryo.  
To understand the effects of this endogenous production of α2m, the mEBs treated with 
varying concentrations of TNFα were analysed for vascularization. Interestingly, TNFα 
concentration of 40ng/ml and above displayed increased vascularization in mEBs. This 
effect could be a result of TNFα stimulating endothelial differentiation pathways through 
the TNFα receptors or through the α2m-LRP1 stimulatory pathway since endogenous 
α2m was strongly upregulated. But another study has reported that mESCs and early 
vascular cells have relatively low expression of TNF receptors and its expression 
increases during differentiation (Zampetaki et al., 2007). This could be one reason why 
TNFα does not induce apoptosis upon its treatment in mEBs but rather plays a role in 
differentiation. To test if LRP1 receptor plays a role in this TNFα mediated 
vascularization, mEBs were treated with TNFα co-treated with anti-LRP1 antibody, 
TNFα alone and anti-LRP1 antibody alone. This resulted in the abolishment of TNFα 
induced vascularization suggesting TNFα may act via the LRP1 receptor.  
TNFα was reported to strongly bind non-covalently to both native and activated forms 
of α2m (Wollenberg et al., 1991). It was also reported that activated form of α2m 
injected onto LPS-treated mice prevented expression of iNOS in liver, kidneys and 
heart leading to their survival compared to untreated controls suggesting therapeutic 
potential of α2m in reversing LPS toxicity induced by TNFα (Webb et al., 1998). To 
understand this we investigated the expression of TNFα in mEBs treated with 
increasing concentrations of α2m. This resulted in dose-dependent down-regulation of 
the endogenous expression of TNFα, suggesting that α2m may bind to TNFα and 
mediates its degradation or gets activated upon binding to TNFα and triggers the LRP1 
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signaling cascade to induce vasculogenesis. This study also signifies the presence of 
endogenous TNFα in differentiating EBs playing a role in early differentiation pathways.  
In summary, the acute phase protein α2m which also was earlier reported to be 
expressed during endothelial differentiation in adult tissues (Sayegh et al., 1997), 
indeed plays a pro-angiogenic role in the developing mEB. α2m treatment in mEBs 
resulted in dose-dependent increase in vascularization through LRP1 and GRP78 
activity as well as dose-dependent decrease in endogenous TNFα expression. These 
results suggest that α2m exerts angiogenic properties in mEBs as well as presumably 
exerts an anti-inflammatory role with TNFα down-regulation.  
Stem cell therapy has long been implicated for vascular regeneration due to the 
vascular differentiation capacity of stem cells. This pro-angiogenic potency of α2m 
could be utilized for clinical therapies to regenerate blood vessels in ischemic vascular 
injury diseases.  
Inflammation is necessary for normal wound healing, but persistent and chronic 
inflammation leads to non-healing wounds. Treatments aimed at immune suppression 
under such conditions can improve healing process. The anti-inflammatory role of α2m 
along with its angiogenic property may be a potential strategy for treatment of non-
healing wounds. α2m could reduce inflammation induced by TNFα which would aid in 
natural healing processes as well as in the generation of new blood vessels to patch up 
the wound in a regenerative way. Whether α2m could be injected directly onto an 
injured wound is still questionable because the effects of α2m on terminally 
differentiated cells still needs to be investigated. Our study demonstrates the 
angiogenic capacity of α2m in early ESCs. Hence we hypothesize that stem cell 
treatment with addition of α2m could contribute to  better blood vessel regeneration 
along with lowering the adverse effects of inflammation. 
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6. Summary 
α2m the largest non-immunoglobulin protein present in blood plasma of mammals is an 
acute phase protein with its serum level elevated upon tissue damage and 
inflammation. In this study α2m administration in mEBs during early differentiation 
processes resulted in an enhancement of vascularization as assessed with PECAM1 
and VE-Cadherin immunofluorescence studies. α2m stimulated a dose-dependent 
increase in protein expression of the endothelial specific markers PECAM1, FLK1 and 
VE-Cadherin along with up-regulation of the angiogenic growth factors FGF2, VEGF-
165 and PDGF-BB. α2m modulates it activity upon binding to and activating its 
receptors LRP1 and GRP78. Upon blocking with specific antibodies α2m mediated 
vascularization was abolished. Moreover the LRP1 antagonist RAP and inhibitors of the 
angiogenic growth factors blunted the expression of the growth factors FGF2, VEGF-
165 and PDGF-BB along with abolishment of vascularization, suggesting the role of 
LRP1 receptor in triggering endothelial differentiation signaling. α2m treatment also 
resulted in the activation of ERK1/2, PI3K, AKT and STAT3 which are all implicated in 
angiogenic signaling cascades. Their subsequent blocking with their respective 
inhibitors resulted in the abolishment of vascularization.  Investigating the functional 
characteristic of α2m under systematic in-vitro analysis of sprout formation revealed 
that α2m stimulates endothelial cell proliferation and migration inducing vessel 
formation with longer and branched sprouts. 
Induction of inflammation in mEBs upon treatment with the inflammatory cytokine TNFα 
stimulated upregulation of α2m and its receptor LRP1 along with increase in 
vascularization. The vascularization induced by TNFα was abolished upon antibody 
blocking of the receptor LRP1 suggesting its activation in triggering increased 
vascularization. In contrast α2m treatment resulted in a dose-dependent decrease in 
the expression of intrinsic TNFα along with increase in vascularization, suggesting α2m 
mediates TNFα removal by activating LRP1 signaling which could also be responsible 
for enhanced vascularization in mEBs. 
In summary this study reports that α2m stimulates vasculogenesis in mESCs with 
upregulation of growth factors and activation of angiogenic signaling pathways. 
Additionally α2m exerts anti-inflammatory effects in mESCs through inhibition of TNFα 
expression. 
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7. Summary (German) 
α2M, das größte nicht-immunglobuläre Protein im Blutplasma von Säugetieren,  ist ein 
Akutphase Protein, dessen Serumwerte im Zuge von Gewebsverletzungen und 
Entzündungen ansteigen. In dieser Studie konnte gezeigt werden, dass die Gabe von 
α2M in der frühen Phase der Differenzierung von mEBs eine verstärkte 
Vaskularisierung zur Folge hatte, was durch Immunfluoreszenz-Untersuchungen für 
PECAM1 und VE-Cadherin nachgewiesen werden konnte. Dabei ist die Stimulierung 
der Expression der endothelspezifischen Marker PECAM1, FLK1 und VE-Cadherin 
sowie die Expression der pro-angiogenen Wachstumsfaktoren FGF2, VEGF165 und 
PDGF-BB durch α2M dosisabhängig. Mittels Aktivierung und Bindung seiner 
Rezeptoren LRP1 und GRP78 wird die Aktivität von α2M moduliert. Dabei hat die 
Blockade der Rezeptoren durch spezifische Antikörper zur Folge, dass der zuvor 
beobachtete Effekt der Vaskularisierung aufgehoben wird. Eine Behandlung mit dem 
LRP Antagonisten RAP und Inhibitoren der pro-angiogenen Wachstumsfaktoren zeigte, 
dass die Expression von FGF2, VEGF165 und PDGF-BB verringert und die 
Vaskularisierung aufgehoben werden konnte. Dies lässt den Schluss zu, dass der 
Rezeptor LRP1 eine steuernde Wirkung im Verlauf der Signalübertragung für die 
endotheliale Differenzierung besitzt. Außerdem zeigte die Behandlung mit α2M eine 
Aktivierung der an der angiogenen Signalkaskade beteiligten Proteine ERK1/2, PI3K, 
AKT und STAT3. Eine Blockade dieser Proteine mit den jeweiligen Inhibitoren hatte 
ebenfalls zur Folge, dass der beobachtete Effekt der Vaskularisierung aufgehoben 
werden konnte. Eine in-vitro Untersuchung des funktionellen Charakters von α2M 
durch einen „sprout-formation assay“ zeigte, dass α2M die Proliferation und Migration 
endothelialer Zellen stimuliert und so die Bildung von langen und verzweigen Gefäßen 
fördert. 
Eine durch die Behandlung mit TNFα induzierte Entzündungsreaktion in den mEBs 
hatte eine Stimulierung der α2M Bildung und einen Anstieg der LRP1 Expression sowie 
eine Zunahme der Vaskularisierung zur Folge. Die TNFα induzierte Vaskularisierung 
konnte durch eine Antikörper vermittelte Blockierung des LRP1 Rezeptors aufgehoben 
werden . Dagegen zeigten sich durch die Behandlung mit α2M eine Verringerung der 
Expression von intrinsischem TNFα sowie Dosis-abhängig ein Anstieg der 
Vaskularisierung. Dies lässt vermuten, dass α2M die Herunterregulation von TNFα 
durch die Aktivierung des LRP1 Rezeptors vermittelt, was auch für die verstärkte 
Vaskularisierung der mEBs verantwortlich sein könnte. 
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Zusammenfassend konnte in dieser Arbeit gezeigt werden, dass α2M die 
Vaskularisierung in mESCs durch eine verstärkte Expression von Wachstumsfaktoren 
und die Aktivierung von pro-angiogenen Signalwegen stimuliert. Zudem zeigt α2M 
durch die Inhibierung der TNFα Expression einen anti-inflammatorischen Effekt in 
mESCs. 
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8. Index of abbreviations 
 
α2m Alpha 2 macroglobulin 
αSMA Alpha Smooth muscle actin 
Ab Antibody 
AD Alzheimer's disease 
AMPK Adenosine monophosphate-activated protein kinase 
ATF6 Activating transcription factor 6 
ATP Adenosine triphosphate 
BMP Bone morphogenic protein 
bFGF Basic fibroblast growth factor 
BSA Bovine serum albumin 
CO2 Carbon dioxide 
CR Complement type repeats 
EB Embryoid body 
ECL Enhanced chemi luminescence 
ECM Extra cellular matrix 
ECs Endothelial cells 
EDTA Ethylene diamine tetra acetic acid 
EGF Epidermal growth factor 
ELISA Enzyme-linked immunosorbent assay 
eNOS Endothelial nitric oxide synthase 
EPCs Endothelial progenitor cells 
ER Endoplasmic reticulum 
ERK1/2 Extracellular signal-regulated kinases 1/2 
ESCs Embryonic stem cells 
FGF2 Fibroblast growth factor 2 
GAPDH Glyceraldehyde 3 phosphate dehydrogenase 
GRP78 Glucose-regulated protein 78 
h Hours 
HRP Horse radish peroxide 
HSP Heat shock protein 
HUVEC Human umbilical vein endothelial cells 
IF Immuno-fluorescence 
IFNƔ Interferon gamma 
iNOS Inducible nitric oxide synthase 
iPSCs Induced pluripotent stem cells 
IRE1  Inositol-requiring enzyme 1 
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ISL1 Insulin gene enhancer protein 1 
JAK Janus kinase 
KDa Kilo Daltons 
Klf4 Kruppel-like factor 4 
KO Knock-out 
LDL Low-density lipoprotein 
LIF Leukemia inhibitory factor 
LPS Lipopolysaccharide 
LRP1 Low density lipoprotein receptor-related protein 1 
LTβ Lymphotoxin-beta 
MAPK Mitogen-activated protein kinases 
mEB Mouse embryoid body 
MEF Mouse embryonic feeders 
mESCs Mouse embryonic stem cells 
MHC Major histocompatibility complex 
min Minute 
MOPS 3-(N-morpholino)propane sulfonic acid 
mTOR Mammalian target of rapamycin 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF Nerve growth factor 
NIH Unit National Institute of Health unit 
NO Nitric Oxide 
ºC Degree Celcius 
Oct4 Octamer-binding transcription factor 4 
PBS Phosphate buffered saline 
PDGF Platelet derived growth factor 
PECAM1 Platelet endothelial cell adhesion molecule 1 
PERK Protein kinase RNA-like endoplasmic reticulum kinase 
PI3K Phosphatidyl inositide 3-kinase 
PKB/AKT Protein kinase B 
PLCγ Phosphoinositide phospholipase C 
PZP Pregnancy zone protein 
RAP Receptor associated protein 
RIPA Radio immune precipitation assay 
Robo Roundabout homolog 1 
rpm Revolutions per min 
RT Room temperature 
s Second 
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SDS Sodium dodecyl sulfate 
SHH Sonic hedgehog  
SMAD2 Mothers against decapentaplegic homolog 2 
SOX2 Sex determining region Y Box 2 
STAT3 Signal transducer and activator of transcription 3 
TBS Tris buffered saline 
TGFβ Transforming growth factor beta 
TNFR Tumor necrosis factor receptor 
TNFα Tumor necrosis factor alpha 
uPA Urokinase-type plasminogen activator 
UPR Unfolded protein response 
VEGF Vascular endothelial growth factor 
VSMCs Vascular smooth muscle cells 
WB Western blot 
(v/v)  volume/volume 
(w/v)  weight/volume 
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